Dehydroepiandrosterone (DHEA): Comprehensive Research Paper on Hormone Replacement Therapy

Table of Contents

  1. Summary
  2. Mechanism of Action
  3. Clinical Indications
  4. Dosing and Administration
  5. Pharmacokinetics
  6. Side Effects and Adverse Reactions
  7. Drug Interactions
  8. Contraindications and Warnings
  9. Special Populations
  10. Monitoring Requirements
  11. Cost and Accessibility
  12. Clinical Evidence and Efficacy
  13. Comparison to Alternatives
  14. Storage and Handling
  15. References

1. Summary

Dehydroepiandrosterone (DHEA) is an endogenous steroid hormone produced primarily by the adrenal cortex, though it's also synthesized in smaller quantities by the gonads and brain. DHEA serves as a precursor to both androgenic and estrogenic sex hormones, functioning as an intermediary in the biosynthesis of testosterone, dihydrotestosterone (DHT), and estradiol. DHEA plays an important role in making the male sex hormone testosterone and the female sex hormone estrogen.

Unique Regulatory Status:

DHEA occupies a distinctive position in the pharmaceutical landscape. Unlike most hormones, DHEA is available both as a:

  1. Dietary supplement (over-the-counter, not FDA-approved for medical use)
  2. FDA-approved prescription medication (Intrarosa - vaginal formulation)

FDA Approval History:

In 2016, the FDA approved prasterone (DHEA) in an intravaginal gel formulation for the treatment of painful sexual intercourse due to vulvovaginal atrophy under the brand name Intrarosa. This was the first prasterone-containing medication to be approved by the FDA.

Historical Regulatory Background:

DHEA was once marketed for weight loss, and in 1985 the FDA banned over-the-counter sales of DHEA. However, since the passage of the Dietary Supplement Health and Education Act of 1994, DHEA has again been widely available in health food stores in the US.

Current Regulatory Status:

Because DHEA is marketed as a nutritional supplement in the US, allowing companies to bypass the rigorous clinical trials required for FDA approval for medicinal use, it has not been subject to the strict quality control measures applied to other drugs. This creates quality variability among over-the-counter DHEA products.

There is no FDA-approved formulation of DHEA or approved formulation of testosterone for women outside of the specific Intrarosa product.

Standard Dosing:

Pharmacokinetics:

Cost:

  • Oral DHEA supplements: $6-10 for 30 tablets (25-50 mg)
  • Intrarosa (vaginal insert): Significantly more expensive (prescription, brand name)
  • Generic availability: DHEA supplements widely available; no generic for Intrarosa

Clinical Use:

FDA-Approved Indications:

  • Moderate to severe dyspareunia (painful intercourse) due to menopause-related vulvovaginal atrophy (vaginal prasterone/Intrarosa only)

Off-Label Uses (varying degrees of evidence):

  • DHEA replacement in women with primary adrenal insufficiency
  • DHEA replacement in women with secondary adrenal insufficiency
  • Quality of life improvement in adrenal insufficiency
  • Fertility enhancement (controversial)
  • Anti-aging (not evidence-based)

Key Characteristics:

  1. Prohormone: DHEA itself has minimal hormonal activity; it must be converted to active androgens (testosterone, DHT) or estrogens (estradiol) to exert significant effects
  2. Tissue-specific conversion: Different tissues express varying levels of enzymes that convert DHEA to active hormones, resulting in tissue-specific effects
  3. Intracrine activity: DHEA can be converted within target cells to active hormones that act locally without entering systemic circulation
  4. Adrenal androgen: Primary circulating androgen in women (along with androstenedione)
  5. Age-related decline: DHEA levels peak in the 20s and decline progressively with age

Most Common Side Effects:

  • Acne (androgenic effect)
  • Hirsutism (excess hair growth in women)
  • Oily skin
  • Hair loss (androgenic alopecia)
  • Mood changes (including mania in susceptible individuals)
  • Decreased HDL cholesterol

Critical Contraindications:

  • Pregnancy (risk of virilization of female fetus)
  • Breastfeeding (may suppress lactation)
  • Hormone-sensitive cancers (breast, prostate, ovarian)
  • Active psychiatric disorders (risk of mania/psychosis)

Important Considerations:

  1. Quality variability: Over-the-counter DHEA supplements vary widely in purity and actual DHEA content
  2. Limited long-term safety data: Most trials are short-duration (3-12 months)
  3. Modest clinical benefits: Evidence for DHEA replacement in adrenal insufficiency shows small, possibly clinically trivial improvements in quality of life
  4. Gender differences: DHEA replacement appears more beneficial in women than men
  5. Not routinely recommended: Most endocrinology societies do not recommend routine DHEA supplementation outside specific clinical scenarios

Goal Relevance:

  • Improve sexual wellness and reduce pain during intercourse for women experiencing menopause-related changes
  • Enhance fertility and support reproductive health in women with adrenal insufficiency
  • Boost energy levels and improve mood for individuals with hormone imbalances
  • Support anti-aging goals by addressing age-related hormone decline
  • Improve skin health by managing acne and reducing excess hair growth in women
  • Aid in hormone optimization for women seeking to balance estrogen and testosterone levels

2. Mechanism of Action

2.1 Biosynthesis of DHEA

Steroidogenic Pathway:

DHEA is produced during steroidogenesis mainly by two classes of steroidogenic enzymes: P450s and hydroxysteroid dehydrogenases. More specifically, DHEA is synthesized from cholesterol via the enzymes cholesterol side-chain cleavage enzyme (CYP11A1; P450scc) and 17α-hydroxylase/17,20-lyase (CYP17A1), with pregnenolone and 17α-hydroxypregnenolone as intermediates.

The pathway proceeds as follows:

Cholesterol
    ↓ (CYP11A1 - P450scc)
Pregnenolone
    ↓ (CYP17A1 - 17α-hydroxylase activity)
17α-Hydroxypregnenolone
    ↓ (CYP17A1 - 17,20-lyase activity)
DHEA

Sites of Production:

  • Primary site: Adrenal cortex (zona reticularis) - produces >90% of circulating DHEA
  • Secondary sites: Gonads (ovaries and testes), brain (local synthesis)
  • Age-related changes: Zona reticularis develops during adrenarche (ages 6-8), leading to increased DHEA production; production peaks in 20s and declines with age

DHEA-Sulfate (DHEA-S) Formation:

DHEA can be sulfated to DHEA-S by the enzyme steroid sulfotransferase (SULT), while the conversion of DHEA-S back to DHEA is mediated by steroid sulfatases (STSs).

Significance of sulfation:

  • DHEA-S is the predominant circulating form (300-500× higher levels than unconjugated DHEA)
  • Sulfation creates a reservoir with extended half-life (7-22 hours vs. 15-38 minutes)
  • Peripheral tissues can desulfate DHEA-S to generate active DHEA locally
  • DHEA-S is water-soluble and easily measured in blood tests

2.2 Conversion to Active Sex Hormones

DHEA as Androgen Precursor:

DHEA functions as a metabolic intermediate in the biosynthesis of the androgen and estrogen sex steroids both in the gonads and in various other tissues. Metabolism of DHEA to active androgens, including testosterone and 5-dihydrotestosterone (DHT), occurs in the gonads, liver, adrenals, and peripheral tissues.

Androgen Synthesis Pathway:

The conversion pathway involves specific enzymes: Most of DHEA is sulfated, and part of DHEA is converted into androstenediol by AKR1C3. DHEA and androstenediol can both be converted into their corresponding Δ4 products by the hydroxysteroid dehydrogenases isoform 3B2, yielding 4-androstenedione (A4) and testosterone, respectively.

DHEA
    ↓ (3β-HSD2)
Androstenedione (A4)
    ↓ (17β-HSD)
Testosterone
    ↓ (5α-reductase)
Dihydrotestosterone (DHT)

Alternative pathway:

DHEA
    ↓ (AKR1C3 - 17-ketosteroid reductase)
Androstenediol (5-Androstenediol)
    ↓ (3β-HSD2)
Testosterone

Estrogen Synthesis Pathway:

DHEA can be converted to estrogens through aromatization:

DHEA
    ↓ (3β-HSD2)
Androstenedione
    ↓ (Aromatase - CYP19A1)
Estrone (E1)
    ↓ (17β-HSD)
Estradiol (E2)

Tissue-Specific Expression:

Different tissues express varying levels of steroidogenic enzymes, leading to tissue-specific hormone production:

  • Adipose tissue: High aromatase expression → predominantly estrogen production
  • Prostate: High 5α-reductase expression → DHT production
  • Muscle: Moderate conversion to testosterone
  • Skin: Variable enzyme expression → androgens and estrogens
  • Bone: Aromatase expression → local estrogen production

2.3 Intracrine Hormonal Activity

Intracrine vs. Endocrine Mechanisms:

For dehydroepiandrosterone, as a precursor of all steroid hormones, intracrine hormonal activity is inherent. With intracrine regulation, DHEA formed in the adrenal glands, when entering the blood of general circulation, reaches the peripheral tissues where, inside the cells themselves, with the help of appropriate enzyme systems, it is transformed into the biologically active steroid hormones estradiol or testosterone which, without leaving the cells, have a biological effect.

Key Features of Intracrine Activity:

  1. Local hormone production: Peripheral cells take up circulating DHEA or DHEA-S and convert it to active hormones intracellularly
  2. Tissue-specific effects: Each tissue's unique enzyme profile determines which hormones are produced
  3. Minimal systemic spillover: Hormones produced intracellularly are rapidly metabolized within the same cell, limiting systemic effects
  4. Paracrine effects: Some locally produced hormones may affect neighboring cells

Clinical Significance:

  • Vaginal DHEA (Intrarosa): Works primarily through intracrine mechanisms - local conversion to estradiol in vaginal tissue with minimal systemic absorption
  • Monitoring limitations: Serum hormone levels may not reflect tissue-specific hormonal effects
  • Individual variability: Genetic variations in enzyme expression lead to inter-individual differences in DHEA effects

2.4 Direct Hormonal Actions of DHEA

Beyond Prohormone Activity:

While DHEA is primarily considered a prohormone, DHEA itself is an active hormone and can operate directly. DHEA has been found to possess some degree of androgenic activity in its own right, acting as a low affinity (Ki = 1 μM), weak partial agonist of the androgen receptor (AR).

Direct Receptor Interactions:

DHEA and its metabolites interact with multiple receptor systems:

  1. Androgen receptor (AR):

    • DHEA: Weak partial agonist (>100× less potent than testosterone)
    • 5-Androstenediol: Moderate AR agonist

  2. Estrogen receptors (ERα and ERβ):

    • DHEA: Weak estrogenic activity
    • 5-Androstenediol: Moderate ERβ agonist

  3. GABA-A receptors:

    • DHEA: Negative allosteric modulator (inhibitory)
    • DHEA-S: Negative allosteric modulator
    • Effects on neurosteroid activity, anxiety, and mood

  4. NMDA receptors:

    • DHEA: Positive allosteric modulator
    • May contribute to neuroprotective effects

  5. Sigma-1 receptors:

    • DHEA: Agonist
    • Potential neuroprotective and cognitive effects

  6. Peroxisome proliferator-activated receptors (PPARα):

    • DHEA metabolites may interact with PPARα
    • Metabolic effects on lipids and glucose

Non-Genomic Effects:

DHEA may also exert rapid, non-genomic effects through:

  • Modulation of cell membrane properties
  • Effects on intracellular signaling cascades
  • Mitochondrial function
  • Antioxidant activity (controversial)

2.5 Metabolic and Physiological Effects

Metabolic Effects:

  • Lipid metabolism: DHEA may modestly improve lipid profiles, though effects are inconsistent
  • Glucose metabolism: Limited evidence for effects on insulin sensitivity
  • Body composition: Controversial effects on lean mass and fat mass
  • Bone metabolism: May support bone density through conversion to estrogens and androgens

Immunological Effects:

  • Immune modulation: DHEA may enhance immune function, particularly in aging individuals
  • Anti-inflammatory: Some evidence for anti-inflammatory properties
  • Th1/Th2 balance: May shift immune response patterns

Neurological Effects:

  • Neuroprotection: Potential protective effects against neurotoxicity
  • Mood regulation: Effects on mood, anxiety, and well-being (mechanisms unclear)
  • Cognitive function: Limited evidence for cognitive benefits

Cardiovascular Effects:

  • Endothelial function: May improve endothelial function in some populations
  • Blood pressure: Variable effects; may decrease or increase depending on dose and population
  • Cardiovascular risk: Long-term effects on cardiovascular outcomes unclear

2.6 Age-Related DHEA Decline

Age-Related Changes:

DHEA and DHEA-S levels follow a characteristic age trajectory:

  • Childhood: Low levels until adrenarche (ages 6-8)
  • Adolescence: Rapid increase during puberty
  • Peak: Highest levels in 20s-30s
  • Decline: Progressive decrease of 2-3% per year after age 30
  • Elderly: Levels 10-20% of peak by age 70-80

Proposed Mechanisms of Decline:

  1. Adrenal involution: Age-related structural changes in adrenal zona reticularis
  2. Enzyme changes: Decreased expression of steroidogenic enzymes
  3. Hormonal regulation: Changes in ACTH sensitivity
  4. Cellular senescence: Accumulation of senescent cells in adrenal cortex

Clinical Significance of Decline:

  • Physiological vs. pathological: Debate over whether age-related decline is physiological adaptation or pathological process
  • Replacement rationale: Age-related decline has been proposed as rationale for DHEA supplementation (controversial)
  • Individual variability: Wide inter-individual variation in DHEA levels at any given age

Relationship to Adrenal Insufficiency:

  • Primary adrenal insufficiency: Complete loss of adrenal DHEA production
  • Secondary adrenal insufficiency: DHEA production often preserved (zona reticularis less ACTH-dependent than cortisol-producing zones)
  • Adrenal insufficiency vs. aging: DHEA levels in treated adrenal insufficiency may be lower than age-matched healthy controls

3. Clinical Indications

3.1 FDA-Approved Indication: Vulvovaginal Atrophy (Intrarosa)

Approved Use:

Intrarosa is FDA approved to help with painful sex caused by menopause, with a recommended dosage of one insert (6.5 mg) vaginally every day at bedtime.

Pathophysiology of Vulvovaginal Atrophy:

Postmenopausal estrogen deficiency leads to:

  • Thinning of vaginal epithelium
  • Decreased vaginal lubrication
  • Loss of vaginal rugae
  • Increased vaginal pH
  • Dyspareunia (painful intercourse)
  • Vaginal dryness, itching, and burning

Mechanism of Action (Vaginal DHEA):

  • Vaginal DHEA is converted locally to estradiol and testosterone in vaginal tissue
  • Intracrine mechanism: Minimal systemic absorption
  • Restores vaginal epithelial thickness and lubrication
  • Normalizes vaginal pH

Clinical Efficacy:

  • Significant improvement in dyspareunia compared to placebo
  • Improvement in vaginal dryness
  • Objective improvement in vaginal maturation index
  • Minimal systemic estrogen absorption (advantage over systemic HRT)

Patient Population:

  • Postmenopausal women with moderate to severe dyspareunia due to vulvovaginal atrophy
  • Alternative to vaginal estrogen therapy
  • May be preferred in women with contraindications to systemic estrogen

3.2 Adrenal Insufficiency - Women

Rationale for DHEA Replacement:

In primary adrenal insufficiency, complete loss of adrenal function results in:

  • Absence of cortisol production → replaced with hydrocortisone
  • Absence of aldosterone production → replaced with fludrocortisone
  • Absence of DHEA production → often not replaced

Clinical Presentation of DHEA Deficiency:

Women with adrenal insufficiency may experience:

  • Decreased libido
  • Reduced sense of well-being
  • Fatigue (beyond that explained by cortisol deficiency)
  • Decreased body hair (loss of axillary and pubic hair)
  • Low mood or depression
  • Decreased bone mineral density

Evidence Base:

DHEA replacement appears most beneficial in women with adrenal insufficiency. A meta-analysis of studies found that DHEA administration in women with primary or secondary adrenal insufficiency results in small improvements in quality of life and mood (depression) but no significant consistent effects on anxiety or sexual function.

Current Recommendations:

It is advised to take into account DHEA replacement medication for female patients who are entering adulthood from adolescence, especially if they are exhibiting signs of adrenal androgen deficit, such as poor energy, decreased libido, and lower quality of life.

Dosing:

The initial recommended dose is 25-50 mg/day, taken as a single oral dose in the morning. The dose can be changed based on clinical response and blood androgen levels.

Monitoring:

Monitoring should be done every six to twelve months, with a focus on weighing the advantages of a higher quality of life against any possible drawbacks, such as hirsutism or acne.

3.3 Adrenal Insufficiency - Men

Limited Evidence:

It is not advised to replace DHEA on a regular basis in men unless there is proof of a combined adrenal and testicular androgen insufficiency.

Rationale for Limited Use in Men:

  • Men produce substantial testosterone from testes
  • Adrenal androgen contribution is minor in men (unlike women)
  • Clinical trials have not demonstrated consistent benefits in men
  • Testosterone levels typically remain normal in men with adrenal insufficiency

Potential Exceptions:

DHEA replacement might be considered in men with:

  • Combined primary adrenal insufficiency AND hypogonadism
  • Documented low serum DHEA-S levels AND symptoms (fatigue, low libido)
  • Inadequate response to glucocorticoid and mineralocorticoid replacement alone

Clinical Trials:

Most studies in men with adrenal insufficiency show:

  • No significant improvement in quality of life
  • No improvement in sexual function
  • No improvement in mood or energy
  • Potential for adverse androgenic effects

3.4 Off-Label Uses (Limited or No Evidence)

Female Sexual Dysfunction:

  • Rationale: DHEA as androgen precursor may improve libido
  • Evidence: Conflicting; some small studies show benefit, others do not
  • Current status: Not FDA-approved for this indication (except vaginal DHEA for dyspareunia)

Anti-Aging:

  • Rationale: Age-related DHEA decline parallels aging; replacement might reverse aging
  • Evidence: No convincing evidence for anti-aging effects
  • Current status: Widely marketed but not evidence-based

Infertility (Diminished Ovarian Reserve):

  • Rationale: DHEA may improve ovarian response in women with poor ovarian reserve
  • Evidence: Some observational data; no large RCTs
  • Current status: Controversial; used by some fertility centers

Depression:

  • Rationale: DHEA may have mood-enhancing effects
  • Evidence: Limited; small studies suggest possible benefit
  • Current status: Not recommended as primary treatment

Systemic Lupus Erythematosus (SLE):

  • Rationale: Immunomodulatory effects of DHEA
  • Evidence: Some small trials showed benefit; larger trials mixed
  • Current status: Not routinely recommended

Osteoporosis:

  • Rationale: Conversion to sex hormones may support bone density
  • Evidence: Inconsistent; no clear benefit demonstrated
  • Current status: Not recommended

Cognitive Function and Dementia:

  • Rationale: Neurosteroid effects may support cognition
  • Evidence: No convincing evidence for cognitive benefits
  • Current status: Not recommended

4. Dosing and Administration

4.1 DHEA Replacement in Adrenal Insufficiency

Standard Dosing Regimen:

The initial recommended dose is 25-50 mg/day, taken as a single oral dose in the morning.

Dose Titration:

The dose can be changed based on clinical response and blood androgen levels:

  • Starting dose: 25 mg daily
  • Target dose: 25-50 mg daily
  • Maximum dose: Generally not to exceed 50 mg daily in women (higher doses increase side effect risk)

Timing:

  • Morning administration preferred: Mimics physiological DHEA secretion pattern (highest in morning)
  • Once daily dosing: DHEA-S long half-life allows once-daily administration
  • With or without food: Can be taken with or without food

Monitoring and Adjustment:

Monitoring should be done every six to twelve months, with a focus on weighing the advantages of a higher quality of life against any possible drawbacks, such as hirsutism or acne.

Laboratory Targets:

  • DHEA-S levels: Target mid-normal to high-normal range for young adult women
  • Testosterone: Monitor to avoid supraphysiologic levels
  • Estradiol: May increase; monitor in context of other HRT

Clinical Response Assessment:

  • Quality of life questionnaires
  • Sexual function assessments
  • Mood and energy self-reports
  • Evaluation of androgenic side effects

4.2 Intravaginal DHEA (Intrarosa)

FDA-Approved Dosing:

Intrarosa is FDA approved to help with painful sex caused by menopause, with a recommended dosage of one insert (6.5 mg) vaginally every day at bedtime.

Administration Instructions:

  1. Insert one suppository deep into vagina using applicator
  2. Administer at bedtime for convenience and to minimize leakage
  3. Use daily for optimal effect
  4. Effects typically seen within 2-4 weeks; maximum benefit at 12 weeks

Duration of Treatment:

  • Long-term use is typically required for sustained benefit
  • Symptoms often recur upon discontinuation
  • Periodic reassessment of need for continued therapy

Monitoring:

4.3 Supplement Use (Non-FDA Approved)

Common Supplement Dosages:

  • Low dose: 10-25 mg daily
  • Moderate dose: 25-50 mg daily
  • High dose: 50-100 mg daily (not recommended without medical supervision)

Safety Considerations:

  • DHEA supplements bypass FDA medication approval process
  • Quality varies widely among manufacturers
  • Actual DHEA content may differ from label claims
  • Contamination with other steroids possible
  • Medical supervision recommended even for OTC use

Risks of Unsupervised Use:

  • Inappropriate dosing
  • Unmonitored hormone levels
  • Androgenic side effects
  • Drug interactions
  • Use in contraindicated conditions

4.4 Special Dosing Considerations

Women with Adrenal Insufficiency:

  • Primary adrenal insufficiency: 25-50 mg daily
  • Secondary adrenal insufficiency: Individualize; may not need DHEA if pituitary androgen production intact
  • Consider patient symptoms: Tailor dose to symptom response

Postmenopausal Women:

  • Systemic symptoms: 25-50 mg daily oral DHEA (off-label)
  • Vulvovaginal atrophy: 6.5 mg intravaginal daily (FDA-approved)

Men:

  • DHEA replacement generally not recommended
  • If used: Lower doses (25 mg daily) may be sufficient
  • Close monitoring for androgenic effects

Elderly:

  • Start at lower end of dosing range (10-25 mg)
  • Increased sensitivity to hormonal effects
  • Monitor for cardiovascular and metabolic effects

4.5 Product Selection and Quality

Prescription vs. OTC:

Prescription (Intrarosa):

  • FDA-approved
  • Consistent quality and dosing
  • Specific indication (vulvovaginal atrophy)
  • More expensive

OTC Supplements:

  • Widely variable quality
  • Not FDA-approved for medical use
  • Lower cost
  • Quality assurance concerns

Choosing High-Quality Supplements:

If using OTC DHEA (despite quality concerns):

  1. Third-party testing: Look for USP, NSF, or ConsumerLab certification
  2. Reputable manufacturers: Choose established supplement companies
  3. Micronized formulations: May have better absorption
  4. Avoid proprietary blends: Should list exact DHEA content
  5. Check expiration dates: Use fresh product

Pharmaceutical-Grade DHEA:

  • Some compounding pharmacies offer pharmaceutical-grade DHEA
  • Higher quality than typical supplements
  • Requires prescription
  • More expensive than OTC but cheaper than branded products

4.6 Missed Doses and Discontinuation

Missed Dose:

  • Take as soon as remembered if within a few hours
  • If near next dose time, skip missed dose
  • Do not double dose

Discontinuation:

  • DHEA can be stopped abruptly without tapering (unlike glucocorticoids)
  • Symptoms related to DHEA deficiency may recur
  • No withdrawal syndrome

Treatment Interruptions:

  • Illness: Continue DHEA at usual dose (no stress-dosing required, unlike hydrocortisone)
  • Surgery: Continue perioperatively
  • No dose adjustment needed for stress (stress-dosing applies to glucocorticoids, not DHEA)

5. Pharmacokinetics

5.1 Absorption

Oral Bioavailability:

Following a 50-mg oral DHEA dose in primates, systemic availability was only 3.1%. The low bioavailability is due to extensive first-pass metabolism.

First-Pass Metabolism:

DHEA is transformed into DHEA-S by sulfation during first-pass metabolism in the liver and intestines when administered orally.

Key Characteristics:

  • Rapidly absorbed from gastrointestinal tract
  • Extensive hepatic and intestinal metabolism on first pass
  • Most absorbed DHEA is converted to DHEA-S
  • Low circulating levels of unconjugated DHEA relative to dose
  • DHEA-S serves as circulating reservoir

Peak Plasma Concentrations:

  • Unconjugated DHEA peaks within 1-3 hours after oral dose
  • DHEA-S levels peak later (4-6 hours) and are sustained
  • Multiple daily doses not required due to DHEA-S reservoir

Food Effects:

  • DHEA absorption not significantly affected by food
  • Can be taken with or without meals
  • Fat content of meal may slightly enhance absorption (minimal clinical significance)

Intravaginal Absorption (Intrarosa):

  • Minimal systemic absorption
  • Primarily local conversion to active hormones in vaginal tissue
  • Serum estradiol and testosterone levels minimally affected
  • Intracrine mechanism limits systemic exposure

5.2 Distribution

Volume of Distribution:

  • Not well-characterized for DHEA
  • Lipophilic steroid distributes widely into tissues
  • Crosses blood-brain barrier

Protein Binding:

  • DHEA: Moderately protein-bound (~90%)
  • DHEA-S: Highly protein-bound (~98%) to albumin
  • Binding to sex hormone-binding globulin (SHBG) is minimal

Tissue Distribution:

DHEA and DHEA-S distribute to:

  • Adipose tissue
  • Muscle
  • Liver
  • Brain
  • Reproductive tissues
  • Bone
  • Skin

5.3 Metabolism

Primary Metabolic Pathways:

The major circulating metabolites of DHEA are DHEA-S, androsterone glucuronide, and androstane-3α,17β-diol-glucuronide.

Sulfation:

  • Primary first-pass metabolic pathway
  • Catalyzed by steroid sulfotransferases (SULT2A1, SULT1E1)
  • Produces DHEA-S (long half-life reservoir)
  • Reversible: Steroid sulfatases can regenerate DHEA

Conversion to Active Hormones:

Serum androstenedione, testosterone, DHEA-S, and various glucuronide metabolites increase following DHEA administration, with greater effects after oral versus percutaneous administration due to gastrointestinal and hepatic metabolism.

Metabolic Enzymes Involved:

  1. 3β-Hydroxysteroid dehydrogenase (3β-HSD2):

    • Converts DHEA → androstenedione

  2. 17-Ketosteroid reductases (AKR1C3):

    • Converts DHEA → androstenediol
    • Converts androstenedione → testosterone

  3. 17β-Hydroxysteroid dehydrogenases (17β-HSD):

    • Interconversion of androgens and estrogens

  4. Aromatase (CYP19A1):

    • Converts androstenedione → estrone
    • Converts testosterone → estradiol

  5. 5α-Reductase:

    • Converts testosterone → DHT

  6. Glucuronidation:

    • Phase II conjugation of DHEA metabolites
    • Enhances water solubility for excretion

Tissue-Specific Metabolism:

Different tissues express varying levels of these enzymes, leading to:

  • Tissue-specific hormone production
  • Individual variability in DHEA effects
  • Gender differences in metabolite profiles

5.4 Elimination

Half-Life:

Routes of Elimination:

Renal Excretion:

  • Primary route for conjugated metabolites (glucuronides, sulfates)
  • Minimal excretion of unconjugated DHEA
  • Water-soluble conjugates excreted in urine

Biliary Excretion:

  • Some metabolites excreted in bile
  • Subject to enterohepatic recirculation
  • Minor contribution to elimination

Metabolic Clearance:

  • Extensive hepatic clearance of unconjugated DHEA
  • Conversion to metabolites is primary clearance mechanism
  • Little unchanged DHEA reaches systemic circulation

5.5 Pharmacokinetic Variability

Age-Related Differences:

  • Elderly: May have reduced clearance and prolonged half-life
  • Hepatic function: Age-related decline in liver function may affect metabolism
  • Enzyme activity: Changes in steroidogenic enzyme expression with aging

Sex Differences:

  • Women: Higher conversion to estrogens (greater aromatase activity in adipose)
  • Men: Higher conversion to potent androgens (DHT)
  • Baseline hormone status: Influences metabolic pathways

Genetic Polymorphisms:

Variations in genes encoding:

  • Steroidogenic enzymes (3β-HSD, 17β-HSD, aromatase)
  • Sulfotransferases and sulfatases
  • Phase II conjugation enzymes
  • Result in inter-individual variability in DHEA effects

Drug Interactions Affecting Pharmacokinetics:

  • CYP3A4 inhibitors: May alter metabolism of DHEA and its downstream metabolites
  • Enzyme inducers: May enhance clearance
  • See Section 7 for detailed drug interactions

5.6 Pharmacodynamics

Concentration-Effect Relationships:

  • Dose-dependent increases in DHEA-S: Linear relationship up to ~100 mg daily
  • Testosterone and estradiol increases: Dose-dependent but subject to individual variability
  • Clinical effects: Poor correlation between serum levels and subjective benefits

Gender-Specific Pharmacodynamics:

In women but not in men, DHEA increased testosterone and DHT to levels above gender-specific young adult ranges. The magnitude of testosterone increment was higher in females compared to men.

Time to Steady State:

  • DHEA-S steady state achieved within 7-10 days of daily dosing
  • Downstream hormone steady states achieved within 2-4 weeks
  • Clinical effects may take 4-12 weeks to manifest

Duration of Action:

  • Hormonal effects persist for 24 hours after single dose (due to DHEA-S reservoir)
  • Clinical effects (mood, well-being) may have delayed onset and offset
  • Cessation results in return to baseline within 2-4 weeks

6. Side Effects and Adverse Reactions

6.1 Overview of Safety Profile

General Tolerability:

DHEA is generally well tolerated in studies of adrenal insufficiency, though data from long-term studies are lacking. Researchers don't know enough about the long-term effects of DHEA use, and there's some concern that using DHEA supplements for long periods could be harmful.

Evidence from Clinical Trials:

In clinical trials, adverse events were minimal, the most common being application-site reaction, acne, breast pain, headache, and hirsutism, with all metabolic markers remaining stable, including liver enzymes, serum lipids, complete blood cell counts, and metabolic panels.

6.2 Androgenic Side Effects

Common Androgenic Effects:

Androgenic side effects (acne and hirsutism) appear to be more common with DHEA than placebo, depending on the dose administered and targeted DHEA levels.

Acne:

  • Mechanism: Increased androgen stimulation of sebaceous glands
  • Frequency: Common, especially at doses >50 mg daily
  • Presentation: Typically facial acne; may also affect chest and back
  • Management:
    • Reduce DHEA dose
    • Topical acne treatments
    • Consider discontinuation if severe
  • Reversibility: Resolves upon dose reduction or discontinuation

Hirsutism (Excess Body/Facial Hair):

  • Mechanism: Androgen-stimulated hair follicle growth
  • Frequency: Common in women, especially at higher doses
  • Presentation:
    • Increased facial hair (upper lip, chin)
    • Increased body hair (chest, abdomen, thighs)
  • Management:
    • Reduce DHEA dose
    • Cosmetic hair removal
    • May require discontinuation
  • Reversibility: Partially reversible; existing hair growth may persist

Androgenic Alopecia (Hair Loss):

  • Mechanism: Androgen-sensitive hair follicles (scalp)
  • Frequency: Uncommon but concerning when occurs
  • Presentation: Pattern baldness in predisposed individuals
  • Management:
    • Discontinue DHEA
    • Consider minoxidil or other hair loss treatments
  • Reversibility: May be partially reversible if caught early

Oily Skin:

Negative side effects are overall rare and relatively mild, including oily skin, acne and hair loss, all of which are immediately reversible with lowering of DHEA dosage (usually 25 mg three times daily) or discontinuation of supplementation.

Voice Deepening (Rare):

  • Mechanism: Androgenic effect on larynx
  • Frequency: Rare, typically only with prolonged high doses
  • Reversibility: Irreversible if occurs

Clitoromegaly (Rare):

  • Mechanism: Androgenic stimulation of genital tissue
  • Frequency: Rare
  • Reversibility: May be irreversible

6.3 Estrogenic Side Effects

Breast Tenderness:

  • Mechanism: Conversion to estrogens, estrogenic stimulation of breast tissue
  • Frequency: Common
  • Management:
    • Typically mild and self-limited
    • Reduce dose if persistent
  • Reversibility: Resolves with dose reduction or discontinuation

Gynecomastia (Men):

Hormonal effects include gynecomastia and testicular wasting in males.

  • Mechanism: Excess estrogen from DHEA aromatization
  • Frequency: Uncommon in men at replacement doses
  • Management:
    • Discontinue DHEA
    • Evaluate for other causes
    • May require surgical intervention if persistent
  • Reversibility: Variable

Testicular Atrophy (Men):

Hormonal effects include gynecomastia and testicular wasting in males.

  • Mechanism: Suppression of gonadotropins (LH, FSH) by increased androgens/estrogens
  • Frequency: Rare, primarily with supraphysiologic doses
  • Management:
    • Discontinue DHEA
    • Monitor testosterone and gonadotropins
  • Reversibility: Typically reversible upon discontinuation

6.4 Psychiatric and Neurological Effects

Mania and Hypomania:

Mania and hypomania have occurred in patients both with and without a psychiatric history, and these reactions appear to be related to higher doses. Observed adverse effects include mania and hypomania.

  • Mechanism: Not fully understood; may involve neurosteroid effects
  • Risk factors:
    • Personal or family history of bipolar disorder
    • Higher doses (>50 mg daily)
  • Presentation:
    • Elevated mood
    • Decreased need for sleep
    • Increased energy and activity
    • Impulsivity
    • Rapid speech
  • Management:
    • Immediate discontinuation
    • Psychiatric evaluation
    • Mood stabilizers if indicated
  • Contraindication: DHEA should not be used in individuals with bipolar disorder

Other Psychiatric Effects:

Use caution in individuals with psychiatric disorders; agitation, confusion, anxiety, paranoia, and suicidal thoughts have been reported.

Headache:

  • Common adverse effect in clinical trials
  • Typically mild
  • May resolve with continued use

Insomnia:

  • Stimulatory effects in some individuals
  • Taking earlier in day may help
  • Consider dose reduction

6.5 Cardiovascular and Metabolic Effects

Blood Pressure Effects:

Hormonal effects include unfavorable effects on blood pressure in both males and females.

  • Mechanism: Mineralocorticoid effects; vascular effects of androgens
  • Clinical significance: Variable; monitor blood pressure

Lipid Effects:

Hormonal effects include unfavorable effects on lipid metabolism (decreased HDL levels) in both males and females. Observed adverse effects include decreased HDL levels.

  • HDL cholesterol: May decrease (unfavorable)
  • LDL cholesterol: Variable effects
  • Triglycerides: Variable effects
  • Clinical significance: Monitor lipid panel; consider impact on cardiovascular risk

Insulin Resistance:

  • Limited evidence; effects unclear
  • Monitor in diabetic patients

Arrhythmias:

  • Rare reports
  • Palpitations occasionally reported
  • Causality uncertain

6.6 Hepatic Effects

Liver Enzyme Elevations:

Hepatotoxicity:

  • Rare
  • More concern with oral androgen supplements in general
  • Discontinue if liver enzyme elevations occur

6.7 Application Site Reactions (Intravaginal DHEA)

Common with Intrarosa:

The most common being application-site reaction.

  • Vaginal discharge
  • Vaginal discomfort
  • Vaginal irritation
  • Pelvic pain

Management:

  • Typically mild and transient
  • Resolve with continued use or dose adjustment
  • Discontinue if severe

6.8 Other Adverse Effects

Fatigue:

  • Paradoxically reported despite use for fatigue
  • May reflect individual variability or other factors
  • Consider dose adjustment

Abdominal Pain:

  • Occasional reports
  • Typically mild
  • Unclear causality

Nausea:

  • Uncommon
  • May improve if taken with food

6.9 Theoretical Long-Term Risks

Cancer Risk:

There are risks associated with using any pre-steroid enhancer, and the higher the dose, the greater the risk.

Hormone-Sensitive Cancers:

  • Concern: DHEA converts to estrogens and androgens, which may stimulate hormone-sensitive tumors
  • Evidence: No long-term safety data in cancer survivors
  • Recommendation: Avoid in patients with history of breast, prostate, ovarian, or endometrial cancer

Prostate Cancer:

  • Theoretical risk in men (androgenic effects)
  • Limited data
  • Monitor PSA in men using DHEA

Endometrial Hyperplasia:

  • Theoretical concern with estrogenic effects
  • Limited evidence with oral DHEA
  • Monitor endometrial thickness in postmenopausal women

Cardiovascular Disease:

  • Long-term cardiovascular effects unknown
  • Lipid changes may increase CV risk
  • Blood pressure effects may be unfavorable
  • Needs long-term safety studies

6.10 Severity and Management

Mild Side Effects:

  • Acne, oily skin, mild hirsutism
  • Management: Dose reduction, topical treatments, patient education

Moderate Side Effects:

  • Significant hirsutism, alopecia, mood changes
  • Management: Dose reduction or discontinuation, specialist referral

Severe Side Effects:

  • Mania/hypomania, severe psychiatric symptoms, signs of hepatotoxicity
  • Management: Immediate discontinuation, emergency psychiatric or medical evaluation

Dose-Related Side Effects:

Most androgenic side effects are dose-related:

  • Consider starting at lower dose (25 mg)
  • Titrate slowly based on clinical response
  • Use minimum effective dose
  • Monitor regularly for adverse effects

7. Drug Interactions

7.1 Overview of Interaction Potential

Number of Known Interactions:

There are 192 drugs known to interact with DHEA, including 40 major, 128 moderate, and 24 minor interactions.

Mechanisms of Interaction:

  1. Pharmacokinetic interactions: DHEA affects hepatic/intestinal enzyme CYP3A4 metabolism
  2. Pharmacodynamic interactions: Hormonal effects of DHEA and its metabolites
  3. Additive effects: Combination with other hormones
  4. Antagonistic effects: Reduction in efficacy of certain medications

7.2 Major Drug Interactions (Contraindicated or Avoid)

Pimozide:

DHEA increases pimozide levels and is contraindicated due to risk of QT interval prolongation.

  • Mechanism: CYP3A4 inhibition
  • Risk: QT prolongation, ventricular arrhythmias, sudden death
  • Recommendation: Contraindicated

Tuberculosis Vaccine (Live):

DHEA might reduce the effects of the tuberculosis vaccine and should not be taken when receiving it.

  • Mechanism: Immunomodulatory effects
  • Recommendation: Avoid concurrent use

7.3 Moderate Drug Interactions (Use with Caution)

CYP3A4 Substrates:

DHEA affects hepatic/intestinal enzyme CYP3A4 metabolism, increasing levels of medications like dihydroergotamine and everolimus.

Drugs with increased levels:

  • Dihydroergotamine
  • Everolimus
  • Tacrolimus
  • Cyclosporine
  • Many others metabolized by CYP3A4

Management:

  • Monitor drug levels
  • Watch for toxicity
  • Consider dose adjustments

Antidepressants:

Taking DHEA with antidepressants might increase the risk for serious side effects.

  • Mechanism: Additive effects on serotonin; hormonal effects on mood
  • Specific concerns: Risk of mania with tricyclic antidepressants, SSRIs, SNRIs
  • Management:
    • Use with caution in patients on antidepressants
    • Monitor mood closely
    • Watch for signs of mania/hypomania

Estrogens:

DHEA might increase estrogen levels, and taking it with estrogen might cause too much estrogen in the body.

  • Mechanism: DHEA converts to estradiol; additive estrogenic effects
  • Side effects: Breast tenderness, nausea, bloating, increased cancer risk
  • Management:
    • Monitor estradiol levels
    • Watch for estrogenic side effects
    • Consider reducing estrogen dose

Testosterone:

Taking DHEA with testosterone might cause too much testosterone, increasing effects and side effects.

  • Mechanism: DHEA converts to testosterone; additive androgenic effects
  • Side effects: Acne, hirsutism, aggression, lipid changes
  • Management:
    • Monitor testosterone levels
    • Watch for androgenic side effects
    • Adjust doses as needed

Aromatase Inhibitors:

  • Mechanism: Aromatase inhibitors block conversion of DHEA to estrogens
  • Effect: May reduce estrogenic benefits of DHEA; increase androgenic effects
  • Clinical significance: DHEA may partially counteract aromatase inhibitor effects
  • Management: Consider avoiding combination in breast cancer patients on aromatase inhibitors

7.4 Endocrine System Interactions

Insulin and Oral Hypoglycemics:

DHEA can affect how insulin works in the body; people with diabetes should monitor blood sugar carefully.

  • Mechanism: DHEA may affect insulin sensitivity and glucose metabolism
  • Effect: Variable effects on blood glucose
  • Management:
    • Monitor blood glucose closely
    • Adjust antidiabetic medication doses as needed
    • Frequent monitoring during DHEA initiation

Thyroid Hormones:

  • Potential interaction: Hormonal interplay
  • Clinical significance: Unclear
  • Management: Monitor thyroid function tests if both used

Glucocorticoids:

  • Mechanism: DHEA may modulate glucocorticoid effects
  • Clinical significance: Unclear interactions
  • Management: Monitor when used together (common in adrenal insufficiency)

7.5 Cardiovascular Medications

Blood Thinners (Anticoagulants/Antiplatelets):

DHEA may interact with blood thinners.

  • Mechanism: Potential effects on platelet function or coagulation factors
  • Specific drugs: Warfarin, aspirin, clopidogrel, others
  • Management:
    • Monitor INR closely in patients on warfarin
    • Watch for bleeding signs
    • Consider more frequent monitoring

Antihypertensives:

  • Mechanism: DHEA may affect blood pressure
  • Effect: May reduce effectiveness of antihypertensive medications or have additive effects
  • Management: Monitor blood pressure regularly

7.6 Psychiatric Medications

Lithium:

  • Mechanism: Hormonal effects on mood; potential drug interaction
  • Risk: Mood destabilization
  • Management: Use with extreme caution; close psychiatric monitoring

Antipsychotics:

  • See pimozide (contraindicated)
  • Other antipsychotics may interact via CYP3A4 or pharmacodynamic effects
  • Use with caution

7.7 Cancer Treatments

Hormone Therapies:

  • Tamoxifen, raloxifene (SERMs): DHEA may counteract effects
  • GnRH agonists/antagonists: Hormonal interference possible
  • Management: Generally avoid DHEA in patients on cancer hormone therapy

Chemotherapy:

  • Limited interaction data
  • CYP3A4 interactions possible
  • Oncologist consultation recommended

7.8 Herbs and Supplements

Other Hormone Supplements:

  • Androgen precursors (androstenedione, etc.): Additive androgenic effects
  • Estrogen-containing herbs (black cohosh, red clover, etc.): Additive estrogenic effects
  • Management: Avoid combining multiple hormone supplements

St. John's Wort:

  • Mechanism: CYP3A4 induction
  • Effect: May reduce DHEA and metabolite levels
  • Management: Monitor for reduced efficacy

Licorice:

  • Mechanism: Glycyrrhizin has mineralocorticoid effects
  • Effect: Additive effects on electrolytes and blood pressure
  • Management: Use caution with combination

7.9 Alcohol

Acute Alcohol Use:

  • May affect metabolism
  • Additive CNS effects possible
  • Moderate alcohol intake likely safe

Chronic Alcohol Use:

  • May affect hepatic metabolism
  • Monitor liver function
  • Use with caution

7.10 Clinical Management of Drug Interactions

Pre-Treatment Assessment:

  • Obtain complete medication list (including OTC and supplements)
  • Screen for major interactions
  • Consider alternatives if high-risk interactions present

Monitoring:

  • Drug levels when indicated
  • Clinical response and side effects
  • Relevant laboratory parameters (hormones, lipids, liver enzymes, etc.)

Patient Education:

  • Inform patients about potential interactions
  • Advise against starting new medications or supplements without medical consultation
  • Report new symptoms or changes in condition

8. Contraindications and Warnings

8.1 Absolute Contraindications

Pregnancy:

DHEA is possibly unsafe when taken during pregnancy or breast-feeding, as it can cause higher than normal levels of a male hormone called androgen.

No reports investigating the potential teratogenic effects from use of dehydroepiandrosterone (DHEA) in human pregnancy have been located. However, animal reproduction data suggest that DHEA and/or DHEA-S may cause virilization of the external genitalia in female fetuses and inhibit implantation or development of the pregnancy when administered shortly after conception.

Risks to fetus:

  • Virilization of female fetuses
  • Ambiguous genitalia
  • Disruption of normal sexual development
  • Potential impairment of implantation

Recommendation:

Breastfeeding:

DHEA is possibly unsafe during breast-feeding, as it can cause higher than normal levels of a male hormone called androgen.

No reports on the use of DHEA during lactation have been located. Research has shown that the amount of lactation in the DHEA-S administrated group was significantly decreased on the second day of the puerperium, suggesting DHEA may interfere with milk production.

Risks:

  • Suppression of lactation
  • Transfer of DHEA and metabolites to breast milk
  • Androgenic effects on infant (theoretical)

Recommendation:

  • Contraindicated during breastfeeding
  • Consider alternatives or postpone treatment until after weaning

Children:

DHEA should not be taken during pregnancy or while breastfeeding, and children should not use it.

Risks:

  • Premature sexual development (precocious puberty)
  • Accelerated bone maturation
  • Growth plate closure
  • Hormonal disruption

Recommendation:

  • Not recommended in prepubertal children
  • Use only under strict medical supervision in adolescents if indicated

Hormone-Sensitive Cancers:

DHEA supplementation should not be used in hormone-dependent breast and prostate cancers.

People with higher risk of prostate, liver, breast or ovarian cancer should not take DHEA.

Specific cancers:

  • Breast cancer (current or history)
  • Prostate cancer (current or history)
  • Ovarian cancer
  • Endometrial cancer
  • Testicular cancer

Rationale:

  • DHEA converts to estrogens and androgens
  • May stimulate hormone-sensitive tumor growth
  • Safety not established in cancer survivors

Recommendation:

  • Absolute contraindication in active hormone-sensitive cancer
  • Use extreme caution (generally avoid) in cancer survivors

Severe Psychiatric Disorders:

DHEA can trigger mania, psychosis, and other mood changes, especially in people with bipolar disorder and other mental health issues.

Specific conditions:

  • Bipolar disorder (mania/hypomania risk)
  • Schizophrenia or psychotic disorders
  • Active suicidal ideation
  • Severe depression with psychotic features

Recommendation:

  • Contraindicated in bipolar disorder
  • Use extreme caution in other psychiatric conditions
  • Psychiatrist consultation required

8.2 Relative Contraindications (Use with Extreme Caution)

Liver Disease:

  • DHEA undergoes extensive hepatic metabolism
  • Risk of hepatotoxicity (rare but documented)
  • Monitor liver function closely
  • Consider avoiding in severe liver disease

Diabetes:

  • DHEA may affect glucose metabolism and insulin sensitivity
  • Monitor blood glucose closely
  • Adjust antidiabetic medications as needed

Cardiovascular Disease:

  • Effects on lipids (decreased HDL) may worsen CV risk
  • Blood pressure effects variable
  • Use with caution in patients with:
    • Coronary artery disease
    • Heart failure
    • Arrhythmias
    • Hypertension

Benign Prostatic Hyperplasia (BPH):

  • Androgenic effects may worsen urinary symptoms
  • Monitor prostate-specific antigen (PSA)
  • Watch for worsening symptoms

Polycystic Ovary Syndrome (PCOS):

  • PCOS patients often have elevated androgens
  • DHEA may worsen hyperandrogenism
  • Use only with specialist supervision

8.3 Warnings and Precautions

Dose-Related Risks:

Do not use DHEA in doses higher than 50-100 mg daily or long-term, as it can increase the risk of serious side effects including cancer.

Recommendation:

  • Limit doses to 25-50 mg daily for replacement therapy
  • Avoid chronic high-dose use
  • Medical supervision essential

Long-Term Safety Unknown:

  • Most trials are 3-12 months duration
  • Long-term safety data lacking
  • Theoretical concerns about chronic hormonal exposure
  • Periodic reassessment of need for continued therapy

Quality Variability (OTC Products):

  • DHEA supplements not subject to FDA quality control
  • Actual DHEA content may vary from label
  • Contamination with other steroids possible
  • Prefer pharmaceutical-grade products when possible

Surgery:

  • Consider discontinuing 2 weeks before elective surgery
  • May affect bleeding risk (theoretical)
  • Hormonal effects during perioperative period unknown

Laboratory Test Interference:

DHEA may affect:

  • Hormone levels (testosterone, estradiol, DHEA-S)
  • PSA (may increase)
  • Lipid panel (may decrease HDL)
  • Inform healthcare providers and lab about DHEA use

8.4 Special Population Warnings

Elderly:

  • Increased sensitivity to hormonal effects
  • Higher risk of adverse effects
  • Start at lower doses
  • Monitor closely

Athletes:

  • DHEA is a banned substance by many sports organizations
  • May result in positive doping tests
  • Check regulations before use

Genetic Males with Gender Dysphoria:

  • DHEA may increase testosterone (undesired)
  • Avoid if seeking estrogen-dominant hormone profile
  • Discuss with gender-affirming care provider

Genetic Females with Gender Dysphoria:

  • DHEA provides androgenic effects
  • May be used as part of masculinizing therapy (specialist supervision)
  • Monitor for desired and undesired effects

8.5 Monitoring and Risk Mitigation

Pre-Treatment Screening:

  • Comprehensive medical history
  • Medication and supplement review
  • Baseline laboratory tests:
    • DHEA-S, testosterone, estradiol
    • Lipid panel
    • Liver function tests
    • PSA (men)
    • Fasting glucose
  • Cancer screening as indicated
  • Psychiatric history

Ongoing Monitoring:

  • Clinical assessment at 3, 6, and 12 months, then annually
  • Hormone levels every 6-12 months
  • Lipid panel annually
  • Liver enzymes if high risk
  • PSA in men annually
  • Signs of androgenic/estrogenic excess
  • Mood and psychiatric status

Patient Education:

  • Recognize signs of serious adverse effects
  • Understand risks and benefits
  • Report new symptoms promptly
  • Avoid pregnancy
  • Inform all healthcare providers about DHEA use

8.6 Drug-Specific Warnings

Intrarosa (Vaginal DHEA):

  • Use only for approved indication (dyspareunia due to vulvovaginal atrophy)
  • Not for systemic androgen replacement
  • Minimal systemic absorption but not zero
  • Monitor for signs of systemic absorption

Compounded DHEA:

  • Quality varies by compounding pharmacy
  • Ensure pharmacy follows USP standards
  • Verify potency and purity when possible

9. Special Populations

9.1 Pregnancy (See Section 8.1 - Absolute Contraindication)

DHEA is contraindicated in pregnancy. See Section 8.1 for detailed discussion of risks and recommendations.

9.2 Lactation (See Section 8.1 - Absolute Contraindication)

DHEA is contraindicated during breastfeeding. See Section 8.1 for detailed discussion of risks and recommendations.

9.3 Pediatric Populations (See Section 8.1 - Absolute Contraindication)

DHEA is contraindicated in children. See Section 8.1 for detailed discussion of risks and recommendations.

9.4 Geriatric Populations

Age-Related DHEA Decline:

DHEA levels decline progressively with age:

  • Peak in 20s-30s
  • Decline 2-3% per year after age 30
  • Levels 10-20% of peak by age 70-80

"Adrenopause" Concept:

The age-related decline in DHEA has been termed "adrenopause," analogous to menopause. However, whether this decline is pathological or physiological remains debated.

Evidence for DHEA Replacement in Healthy Elderly:

There is lack of evidence supporting DHEA for improved overall health for women.

Current Recommendations:

  • DHEA supplementation not recommended for healthy aging
  • No evidence for anti-aging benefits
  • Risks may outweigh benefits in elderly without adrenal insufficiency

Use in Elderly with Adrenal Insufficiency:

When DHEA replacement is indicated (adrenal insufficiency):

  • Start at lower end of dosing range (10-25 mg daily)
  • Increased sensitivity to hormonal effects
  • Monitor more frequently for adverse effects
  • Watch for cardiovascular effects (blood pressure, lipids)

Special Considerations:

  • Polypharmacy: Elderly often take multiple medications; higher drug interaction risk
  • Cognitive impairment: May affect medication adherence
  • Falls risk: Monitor for effects on strength, balance
  • Bone health: Theoretical benefits on bone density unclear
  • Cardiovascular risk: Lipid effects may be more concerning in elderly with existing CV disease

9.5 Women of Reproductive Potential

Contraception Requirement:

Women of reproductive age taking DHEA should:

  • Use effective contraception
  • Understand teratogenic risks
  • Have pregnancy test before starting treatment
  • Discontinue immediately if pregnancy suspected

Fertility Considerations:

DHEA for Infertility (Controversial):

  • Some fertility clinics use DHEA off-label for diminished ovarian reserve
  • Limited evidence from small studies
  • No large RCTs demonstrating benefit
  • Not FDA-approved for this indication
  • Specialist supervision essential

Discontinuation Planning:

  • Stop DHEA once pregnancy achieved
  • Time course for hormone normalization: 2-4 weeks

9.6 Men with Adrenal Insufficiency

It is not advised to replace DHEA on a regular basis in men unless there is proof of a combined adrenal and testicular androgen insufficiency.

Rationale:

  • Men produce substantial testosterone from testes
  • Adrenal androgen contribution minor compared to gonadal
  • Clinical trials show limited benefit in men
  • Risk of androgenic side effects

Exceptions (Consider DHEA):

  • Combined primary adrenal insufficiency AND hypogonadism
  • Low DHEA-S levels AND persistent symptoms despite adequate glucocorticoid/mineralocorticoid replacement
  • Specialist evaluation recommended

Monitoring in Men:

  • Testosterone levels (total and free)
  • PSA (annually)
  • Signs of androgenic excess
  • Prostate symptoms

9.7 Women with Adrenal Insufficiency

It is advised to take into account DHEA replacement medication for female patients who are entering adulthood from adolescence, especially if they are exhibiting signs of adrenal androgen deficit, such as poor energy, decreased libido, and lower quality of life.

Clinical Indications:

  • Primary adrenal insufficiency
  • Secondary adrenal insufficiency (case-by-case basis)
  • Symptoms: Fatigue, low libido, depressed mood, decreased well-being

Evidence Base:

A meta-analysis of studies found that DHEA administration in women with primary or secondary adrenal insufficiency results in small improvements in quality of life and mood (depression) but no significant consistent effects on anxiety or sexual function.

Interpretation:

  • Benefits are modest ("small improvements")
  • Not all women benefit
  • Individualized decision-making essential
  • Monitor response; discontinue if no benefit after 3-6 months

Monitoring:

  • DHEA-S levels every 6-12 months
  • Testosterone and estradiol
  • Androgenic side effects (acne, hirsutism)
  • Quality of life assessments
  • Sexual function questionnaires

9.8 Postmenopausal Women

Vulvovaginal Atrophy (FDA-Approved):

  • Intrarosa (vaginal DHEA 6.5 mg): FDA-approved for dyspareunia
  • See Section 3.1 for detailed discussion

Systemic DHEA (Off-Label):

Rationale:

  • Postmenopausal women have low estrogen and androgen levels
  • DHEA may improve symptoms via conversion to both

Evidence:

  • Limited RCT data for systemic symptoms
  • Variable individual responses
  • Small studies suggest possible benefits on:
    • Sexual function (inconsistent)
    • Mood (modest improvements)
    • Bone density (unclear)
    • Body composition (conflicting data)

Recommendations:

  • Not routinely recommended
  • Consider on individual basis if symptoms persist despite standard HRT
  • Monitor for androgenic and estrogenic effects
  • Specialist consultation advised

9.9 Transgender Individuals

Transgender Men (Assigned Female at Birth):

  • DHEA provides androgenic effects through conversion to testosterone
  • May be used as adjunct to testosterone therapy (specialist supervision)
  • Not a replacement for testosterone
  • Monitor for:
    • Testosterone levels
    • Desired virilization
    • Androgenic side effects
    • Lipid panel
    • Endometrial effects (if uterus present)

Transgender Women (Assigned Male at Birth):

  • DHEA converts to testosterone (undesired)
  • Generally avoid if seeking estrogen-dominant profile
  • May counteract estrogen therapy
  • Discuss with gender-affirming care team

9.10 Athletes and Physical Performance

Doping Status:

  • DHEA is banned by:
    • World Anti-Doping Agency (WADA)
    • International Olympic Committee (IOC)
    • NCAA (college sports)
    • Many professional sports leagues

Performance Enhancement Claims:

  • Marketed for muscle building, strength, performance
  • Limited evidence for performance benefits in athletes
  • Any benefits likely modest and individual-variable

Risks for Athletes:

  • Positive doping tests
  • Androgenic side effects
  • Cardiovascular effects
  • Unfavorable lipid changes

Recommendation:

  • Athletes should not use DHEA
  • Medical exemption may be possible for adrenal insufficiency (case-by-case)

9.11 Patients with Psychiatric Disorders

Bipolar Disorder:

  • Absolute contraindication (see Section 8.1)
  • Risk of mania/hypomania
  • Do not use

Major Depression:

  • Limited evidence for benefit
  • Risk of mood destabilization
  • Use only with psychiatrist consultation
  • Close monitoring essential
  • Not a substitute for standard antidepressant therapy

Anxiety Disorders:

  • No consistent evidence for benefit
  • May worsen anxiety in some individuals
  • Use with caution

Schizophrenia/Psychotic Disorders:

  • Risk of psychotic symptoms
  • Generally avoid
  • If used: Psychiatrist supervision, low doses, close monitoring

9.12 Patients with Cardiovascular Disease

Existing Cardiovascular Disease:

Use DHEA with caution in patients with:

  • Coronary artery disease
  • Heart failure
  • Arrhythmias
  • Hypertension
  • History of stroke/TIA

Concerns:

  • Decreased HDL cholesterol (unfavorable)
  • Variable blood pressure effects
  • Long-term cardiovascular effects unknown

Monitoring:

  • Blood pressure at every visit
  • Lipid panel at baseline and every 6-12 months
  • Signs of heart failure exacerbation
  • Arrhythmias

Risk-Benefit Assessment:

  • Benefits of DHEA for adrenal insufficiency symptoms must outweigh cardiovascular risks
  • Consider alternatives or lower doses
  • Cardiology consultation if significant CV disease

9.13 Patients with Diabetes

Effects on Glucose Metabolism:

DHEA can affect how insulin works in the body; people with diabetes should monitor blood sugar carefully.

Variable Effects:

  • Some studies: Improved insulin sensitivity
  • Other studies: No effect or worsening
  • Individual responses highly variable

Monitoring:

  • Frequent blood glucose monitoring during DHEA initiation
  • HbA1c every 3 months initially
  • Adjust antidiabetic medications as needed
  • Watch for hypoglycemia or hyperglycemia

Recommendations:

  • Start at low dose (25 mg)
  • Titrate slowly
  • Endocrinologist supervision
  • Patient education on glucose monitoring

9.14 Patients with Liver Disease

Hepatic Metabolism:

  • DHEA undergoes extensive first-pass hepatic metabolism
  • Risk of accumulation in severe liver disease
  • Rare reports of hepatotoxicity

Recommendations:

Mild Liver Disease (Child-Pugh A):

  • Use with caution
  • Monitor liver enzymes at baseline and every 3-6 months
  • Standard dosing

Moderate Liver Disease (Child-Pugh B):

  • Use with caution
  • Consider lower starting dose (10-25 mg)
  • Monitor liver enzymes closely
  • Watch for signs of hepatotoxicity

Severe Liver Disease (Child-Pugh C):

  • Generally avoid
  • If benefits outweigh risks: Lowest dose, very close monitoring
  • Hepatologist consultation

Monitoring:

  • Baseline: ALT, AST, alkaline phosphatase, bilirubin
  • Follow-up: Every 3 months for first year, then every 6 months
  • Discontinue if liver enzymes increase >3× ULN

9.15 Patients with Renal Disease

Renal Excretion:

  • DHEA metabolites excreted renally
  • Accumulation possible in severe renal impairment

Recommendations:

Mild to Moderate Renal Impairment (eGFR 30-89):

  • No dose adjustment typically required
  • Standard dosing
  • Monitor for adverse effects

Severe Renal Impairment (eGFR <30):

  • Use with caution
  • Consider lower starting dose
  • Monitor closely

End-Stage Renal Disease (Dialysis):

  • Limited data
  • DHEA not removed by dialysis
  • Start at low dose if indicated
  • Nephrology consultation

Monitoring:

  • Renal function at baseline and periodically
  • Blood pressure (may be affected)
  • Electrolytes if on dialysis

10. Monitoring Requirements

10.1 Pre-Treatment Assessment

Clinical Evaluation:

  1. Comprehensive Medical History:

    • Current symptoms (fatigue, libido, mood, etc.)
    • Past medical history (cancers, psychiatric disorders, CV disease)
    • Medication and supplement list
    • Family history (cancer, psychiatric disorders)

  2. Physical Examination:

    • Blood pressure, heart rate
    • Weight, BMI
    • Signs of androgen excess (acne, hirsutism)
    • Breast examination (women)
    • Prostate examination (men)

  3. Cancer Screening:

    • Age-appropriate screening up to date
    • Mammogram (women per guidelines)
    • PSA (men >50 or high risk)
    • Pap smear (women per guidelines)

  4. Psychiatric Assessment:

    • Mood disorders screening
    • History of bipolar disorder (contraindication)
    • Current psychiatric medications

10.2 Baseline Laboratory Testing

Hormone Levels:

Comprehensive HRT monitoring typically includes estradiol, progesterone, total and free testosterone, DHEA-S, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prolactin.

Essential Tests:

  • DHEA-S: Baseline level before treatment
  • Testosterone (total and free): Especially in women
  • Estradiol: Baseline in women

Additional Hormones (As Indicated):

  • LH, FSH (if gonadal function uncertain)
  • Prolactin (if symptoms suggest hyperprolactinemia)

Metabolic Panel:

  • Fasting glucose or HbA1c: Diabetes screening
  • Lipid panel: Total cholesterol, LDL, HDL, triglycerides
  • Liver function tests: ALT, AST, alkaline phosphatase, bilirubin
  • Basic metabolic panel: Electrolytes, creatinine, eGFR

Additional Tests:

  • PSA (men): Baseline prostate cancer screening
  • Pregnancy test (women of reproductive age): Confirm not pregnant

Timing:

It is recommended that your blood sample is collected between 7 a.m. and 10 a.m. when DHEA-S levels are typically highest.

If you're taking a supplement containing biotin, it is recommended that you wait at least 72 hours from your last dose before sample collection.

10.3 Ongoing Monitoring Schedule

Follow-Up Visits:

Testing frequency varies based on treatment phase - baseline testing occurs before starting therapy, followed by testing 2-4 weeks after initiation or dosage changes, and during maintenance phase, most patients require testing every 6-12 months.

Monitoring Schedule:

Initial Phase (First 3-6 Months):

  • Clinical assessment: At 4-6 weeks, then at 3 months
  • Laboratory testing: At 8-12 weeks after starting
  • Hormone levels: DHEA-S, testosterone, estradiol

Maintenance Phase (After 6 Months):

  • Clinical assessment: Every 6 months for first year, then annually
  • Laboratory testing: Every 6-12 months
  • Comprehensive labs: Annually (lipids, liver enzymes, PSA in men)

10.4 Laboratory Monitoring

Hormone Monitoring:

DHEA-S Levels:

A DHEAS test measures levels of dehydroepiandrosterone sulfate (DHEAS) in your blood, a steroid hormone made by adrenal glands.

  • Frequency: Every 6-12 months
  • Target: Mid-normal to high-normal range for young adult women
  • Interpretation:
    • Too low: Inadequate replacement; consider dose increase
    • Too high: Risk of excessive androgenic effects; consider dose reduction

Testosterone:

Healthcare providers may order tests to check other hormone levels, such as testosterone or estrogen, using the same blood draw.

  • Women: Monitor total and free testosterone
    • Target: Within or slightly above normal premenopausal range
    • Excessive levels: Risk of virilization
  • Men: Monitor to ensure not supraphysiologic
    • DHEA should not significantly increase testosterone in men with normal gonadal function

Estradiol:

  • Women: Particularly if on concurrent estrogen therapy
    • Monitor for excessive estrogenic effects
  • Men: May increase via aromatization
    • Watch for gynecomastia, other estrogenic effects

Metabolic Monitoring:

Lipid Panel:

  • Frequency: Baseline, then every 6-12 months
  • Key parameter: HDL cholesterol (may decrease with DHEA)
  • Clinical significance: Assess cardiovascular risk
  • Action: If HDL significantly declines, consider dose reduction or discontinuation

Fasting Glucose/HbA1c:

  • Frequency: Baseline, then annually (more frequently in diabetics)
  • Monitor for: Changes in glucose metabolism
  • Adjust: Antidiabetic medications as needed

Liver Function Tests:

  • Frequency: Baseline, then as indicated (every 6-12 months if high risk)
  • Monitor for: Hepatotoxicity (rare)
  • Action: Discontinue if liver enzymes >3× ULN

Prostate Monitoring (Men):

PSA (Prostate-Specific Antigen):

  • Frequency: Baseline, then annually in men >50 or high risk
  • Monitor for: Prostate cancer
  • Action: If elevated or increasing, urology referral

Digital Rectal Exam:

  • Per age-appropriate guidelines
  • Assess for prostate enlargement or nodules

10.5 Clinical Monitoring

Symptom Assessment:

Quality of Life:

  • Use validated questionnaires (SF-36, others)
  • Assess energy, mood, overall well-being
  • Compare to baseline

Sexual Function:

  • Validated questionnaires (FSFI for women, IIEF for men)
  • Assess libido, satisfaction, dyspareunia
  • Compare to baseline

Mood and Mental Health:

  • Depression screening (PHQ-9)
  • Anxiety screening (GAD-7)
  • Watch for mania/hypomania

Androgenic Effects:

Skin:

  • Acne severity
  • Oiliness
  • Assess at every visit

Hair:

  • Hirsutism (Ferriman-Gallwey score)
  • Scalp hair loss
  • Assess at every visit

Voice (Women):

  • Deepening (irreversible)
  • Report immediately if noted

Estrogenic Effects:

  • Breast tenderness
  • Vaginal bleeding (postmenopausal women - requires evaluation)
  • Gynecomastia (men)

Cardiovascular Monitoring:

Blood Pressure:

  • At every visit
  • Home monitoring if hypertensive

Weight:

  • At every visit
  • Track trends

Signs of Heart Failure:

  • Dyspnea, orthopnea, edema
  • Particularly in elderly or those with cardiac history

10.6 Safety Monitoring

Adverse Effects Surveillance:

  • Review side effects at every visit
  • Specific questions about:
    • Mood changes (mania, depression, anxiety)
    • Androgenic effects (acne, hair growth/loss)
    • Estrogenic effects (breast changes)
    • Cardiovascular symptoms

Serious Adverse Events:

  • Mania/psychosis: Immediate discontinuation, psychiatric evaluation
  • Severe hepatotoxicity: Discontinue, hepatology referral
  • Signs of malignancy: Appropriate cancer workup

10.7 Efficacy Assessment

Response to Treatment:

Reassess After 3-6 Months:

  • Have symptoms improved?
  • Are benefits outweighing side effects?
  • Are quality of life measures better?

Decision Point:

  • If clear benefit: Continue with ongoing monitoring
  • If no benefit: Consider discontinuation (DHEA may not be beneficial for all)
  • If side effects outweigh benefits: Reduce dose or discontinue

Long-Term Re-Assessment:

  • Periodically reassess need for continued therapy
  • Consider trial off DHEA after 1-2 years to see if still needed
  • Some women may have symptom resolution and not require lifelong treatment

10.8 Patient Self-Monitoring and Education

Home Monitoring:

Symptoms:

  • Keep symptom diary
  • Note energy levels, mood, libido
  • Report new or worsening symptoms

Side Effects:

  • Monitor for acne, hair growth, mood changes
  • Report immediately: Mania, severe mood changes, jaundice

Blood Pressure (If Indicated):

  • Home BP monitoring if hypertensive
  • Technique education

Weight:

  • Weekly weight checks
  • Report sudden changes

Patient Education Topics:

  1. Medication Adherence:

    • Importance of daily dosing
    • What to do if dose missed

  2. Signs of Serious Side Effects:

    • Mania/hypomania symptoms
    • Jaundice (liver toxicity)
    • Chest pain, severe headache

  3. Pregnancy Prevention:

    • Effective contraception essential
    • Discontinue if pregnancy suspected

  4. Drug Interactions:

    • Report all new medications and supplements
    • Avoid starting new hormones without consultation

  5. Follow-Up:

    • Keep appointments
    • Get lab work as scheduled
    • Report symptoms between visits if concerning

11. Cost and Accessibility

11.1 Medication Costs

Oral DHEA Supplements (OTC):

DHEA costs on average about $10.27 per 30, 25mg capsules, though prices start at $8.85 at some pharmacies. DHEA costs approximately $6 for a supply of 30, 50 mg tablets.

Price Range by Strength:

  • 25 mg: $6-11 for 30 capsules
  • 50 mg: $6-10 for 30 tablets
  • 100 mg: $15-20 for 30 capsules (less common)

Monthly Cost Estimates:

Typical Replacement Dose (25 mg daily):

  • 30 tablets per month
  • Cost: $6-11 per month
  • Annual cost: $72-132

Higher Dose (50 mg daily):

  • 30 tablets per month
  • Cost: $6-10 per month
  • Annual cost: $72-120

Bulk Purchasing:

The normal retail cost of DHEA without health insurance is $31.56 per 1, 90 Capsules Bottle.

  • 90-day supply typically offers savings
  • Example: $31.56 for 90 capsules (50 mg) = $0.35 per tablet
  • Monthly cost for 50 mg daily: ~$10.50

Intrarosa (Vaginal DHEA - Prescription):

Intrarosa costs on GoodRx are significantly higher than oral DHEA supplements:

  • Brand name prescription
  • Typical cost: $300-500 for 28 inserts
  • Monthly cost: $300-500
  • Annual cost: $3,600-6,000

Comparison:

  • Intrarosa vastly more expensive than oral DHEA
  • Prescription required
  • Insurance may or may not cover

11.2 Generic Availability

Oral DHEA:

PRASTERONE also known as DEHYDROEPIANDROSTERONE (DHEA) is the generic form of DHEA.

Status:

  • Widely available as dietary supplement (not FDA-approved as medication except Intrarosa)
  • Multiple manufacturers
  • Quality varies significantly
  • No prescription required for supplements

Intrarosa:

  • Brand name prescription product
  • No generic version currently available
  • Patented formulation

11.3 Insurance Coverage

Oral DHEA Supplements:

DHEA is currently not covered by any Medicare plans, and coverage varies by individual insurance plans.

Reasons for Non-Coverage:

  • Classified as dietary supplement, not prescription medication
  • No FDA approval for medical indications (except Intrarosa)
  • Generally considered OTC product

Out-of-Pocket:

  • Patients pay full cost
  • Relatively affordable ($6-11/month)

Intrarosa (Prescription):

Medicare Part D:

  • May cover Intrarosa (prescription medication)
  • Coverage varies by plan
  • May require prior authorization

Commercial Insurance:

  • Coverage varies widely
  • May require prior authorization
  • Often high copay due to brand name
  • Step therapy may be required (try vaginal estrogen first)

Medicaid:

  • Coverage varies by state
  • Prior authorization likely required

11.4 Discount Programs and Patient Assistance

Prescription Discount Cards:

GoodRx:

SingleCare:

  • Free discount program
  • Similar discounts to GoodRx
  • May offer better prices at certain pharmacies

Manufacturer Programs:

Intrarosa:

  • Manufacturer may offer patient assistance program or copay cards
  • Check manufacturer website or call patient assistance hotline
  • Eligibility varies (income-based or insurance-based)

Charitable Programs:

For Low-Income Patients:

  • Patient advocate foundations
  • Disease-specific charities (adrenal insufficiency organizations)
  • Free clinic networks
  • Sliding fee scale programs

NeedyMeds:

  • Free information on patient assistance programs
  • Database of programs by medication and condition

11.5 Access Barriers and Solutions

Quality Variability (OTC DHEA):

Problem:

Solutions:

  • Choose brands with third-party testing (USP, NSF, ConsumerLab)
  • Prefer pharmaceutical-grade DHEA from compounding pharmacies (requires prescription)
  • Purchase from reputable retailers
  • Avoid suspiciously cheap products

Prescription Access (Intrarosa):

Barriers:

  • Requires prescription from healthcare provider
  • High cost ($300-500/month)
  • Insurance coverage variable
  • Prior authorization delays

Solutions:

  • Discuss with gynecologist or primary care provider
  • Use manufacturer copay cards if eligible
  • Consider vaginal estrogen alternatives (may be less expensive)
  • Appeal insurance denials with medical necessity documentation

Compounded DHEA:

Advantages:

  • Pharmaceutical-grade quality
  • Custom dosing (e.g., 10 mg, 25 mg, 50 mg)
  • May be more affordable than Intrarosa for vaginal formulations

Barriers:

  • Requires prescription
  • Not all compounding pharmacies make DHEA
  • Cost varies by pharmacy
  • Insurance rarely covers compounded medications

Solutions:

  • Find compounding pharmacy specializing in hormones
  • Compare prices among local compounding pharmacies
  • Discuss with prescriber about compounded alternatives to brand products

11.6 International Access

Availability in Other Countries:

  • DHEA availability varies widely internationally
  • Some countries: OTC supplement (like US)
  • Other countries: Prescription required
  • Some countries: Banned or restricted

Examples:

  • Canada: Prescription required
  • European Union: Variable by country; often prescription or restricted
  • Australia: Prescription required
  • Mexico: Often available OTC

Traveling with DHEA:

  • Carry medication in original container
  • Bring prescription or doctor's letter (even for OTC in US)
  • Research destination country regulations
  • Some countries may not allow import

Purchasing Internationally:

  • Quality concerns with international supplements
  • Legality of importing varies
  • US customs may seize shipments
  • Recommend purchasing from US sources

11.7 Cost-Effectiveness

Oral DHEA vs. Alternatives:

DHEA Supplement: $6-11/month Prescription Testosterone (Women): Not FDA-approved; compounded testosterone more expensive Estrogen Therapy: $10-50/month (doesn't provide androgen replacement)

Cost-Effectiveness Assessment:

For Adrenal Insufficiency:

  • DHEA is very affordable
  • If effective, high value for modest cost
  • Main limitation: Variable efficacy (not all benefit)

For Vulvovaginal Atrophy:

  • Intrarosa: $300-500/month (expensive)
  • Vaginal estrogen cream: $30-100/month (less expensive alternative)
  • Cost-effectiveness of Intrarosa questionable given alternatives

Decision Factors:

  • Symptom severity
  • Response to treatment
  • Side effect profile
  • Insurance coverage
  • Patient preferences

12. Clinical Evidence and Efficacy

12.1 Evidence Base Overview

Quality of Evidence:

  • Most DHEA research consists of small trials (n<100) with short duration (3-12 months)
  • Limited large-scale, long-term RCTs
  • Evidence strongest for adrenal insufficiency in women
  • Evidence weak or absent for anti-aging, general wellness, athletic performance

FDA Approval Status:

12.2 DHEA in Women with Adrenal Insufficiency

Meta-Analysis Findings:

A systematic review offers evidence of a small and perhaps clinically trivial effect of DHEA on health-related quality of life (HRQOL) in women with adrenal insufficiency treated for a period of 3–12 months.

There was a small beneficial effect of DHEA on depression; favorable effects on anxiety and sexual well-being were not statistically significant.

A meta-analysis of 10 studies analyzing DHEA administration in women with primary or secondary adrenal insufficiency found marginal improvements in quality of life and mood, but no changes in anxiety and sexual function.

Interpretation of Meta-Analysis:

  • Effect size: Small ("marginal improvements")
  • Clinical significance: Questionable ("perhaps clinically trivial")
  • Consistency: Some outcomes (mood/depression) showed benefit; others (anxiety, sexual function) did not
  • Individual variation: Not all women benefit

Landmark Trials:

NEJM 1999 Study (Arlt et al.):

Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency - New England Journal of Medicine

  • Design: Double-blind, placebo-controlled crossover trial
  • Participants: 24 women with adrenal insufficiency
  • Dose: 50 mg daily for 4 months
  • Key findings:
    • Improved well-being and sexuality scores
    • Increased serum androgens (DHEA-S, testosterone, androstenedione)
    • Modest improvements in mood and fatigue
  • Limitations: Small sample, short duration, crossover design

Long-Term DHEA Replacement Trial:

Long-Term DHEA Replacement in Primary Adrenal Insufficiency: A Randomized, Controlled Trial - PMC

  • Design: Randomized, double-blind, placebo-controlled
  • Duration: 12 months
  • Participants: Women with primary adrenal insufficiency
  • Dose: 25-50 mg daily (individualized)
  • Key findings:
    • Sustained improvements in well-being
    • Benefits maintained over 12 months
    • Adverse effects (acne, oily skin) minimal
  • Conclusion: Long-term DHEA replacement safe and modestly beneficial

12.3 DHEA in Men with Adrenal Insufficiency

Limited Evidence:

It is not advised to replace DHEA on a regular basis in men unless there is proof of a combined adrenal and testicular androgen insufficiency.

Clinical Trials in Men:

NEJM 2006 Study (Nair et al.):

DHEA in Elderly Women and DHEA or Testosterone in Elderly Men | New England Journal of Medicine

  • Participants: Elderly men (age 60+)
  • Dose: 75 mg daily DHEA
  • Duration: 2 years
  • Key findings:
    • DHEA increased DHEA-S and testosterone levels
    • No significant improvement in body composition, physical performance, or insulin sensitivity
    • No improvement in quality of life
  • Conclusion: DHEA not beneficial in elderly men

Why Men Don't Benefit:

  • Men produce substantial testosterone from testes
  • Adrenal androgens contribute minimally to total androgen pool
  • DHEA replacement doesn't significantly increase total androgens in men with normal gonadal function
  • Clinical symptoms of adrenal insufficiency in men rarely related to DHEA deficiency

12.4 Intravaginal DHEA for Vulvovaginal Atrophy

FDA Approval Basis:

  • Phase 3 clinical trials demonstrating efficacy for dyspareunia
  • Objective improvements in vaginal maturation index
  • Minimal systemic absorption
  • Well-tolerated with minimal side effects

Efficacy Data:

  • Significant reduction in dyspareunia severity
  • Improvement in vaginal dryness
  • Improvement in vaginal pH
  • Comparable efficacy to vaginal estrogen in some studies

Advantages vs. Vaginal Estrogen:

  • Minimal systemic estrogen exposure
  • May be preferred in women with contraindications to systemic estrogen
  • Once-daily administration

Limitations:

  • Expensive compared to vaginal estrogen
  • No generic available
  • Similar local side effects (discharge, irritation)

12.5 DHEA for Anti-Aging and General Wellness

Claims:

  • Widely marketed for anti-aging
  • Claims of improved energy, vitality, muscle mass, cognitive function
  • "Fountain of youth" hormone

Evidence:

There is lack of evidence supporting DHEA for improved overall health for women.

Systematic Reviews:

  • Body composition: No consistent benefit on lean mass or fat mass
  • Bone density: No convincing evidence for fracture prevention
  • Cognitive function: No benefit demonstrated
  • Cardiovascular health: No benefit; possible harm (decreased HDL)
  • Longevity: No evidence for life extension

2024 Expert Consensus:

Researchers don't know enough about the long-term effects of DHEA use, and there's some concern that using DHEA supplements for long periods could be harmful.

Recommendation:

  • DHEA not recommended for anti-aging or general wellness
  • No evidence of benefit in healthy elderly
  • Risks may outweigh theoretical benefits

12.6 DHEA for Sexual Function

Women:

DHEA treatment significantly improved overall wellbeing as well as scores for depression, anxiety, and their physical correlates. Furthermore, DHEA significantly increased both sexual interest and the level of satisfaction with sex.

However:

Meta-analyses show inconsistent effects:

  • Some trials: Improvement in sexual interest and satisfaction
  • Other trials: No significant effect
  • Overall: Mixed evidence, small effect sizes

Men:

  • No consistent evidence for benefit
  • DHEA not recommended for male sexual dysfunction
  • Testosterone therapy more appropriate if androgen deficiency documented

12.7 DHEA for Depression

Rationale:

  • DHEA has neurosteroid effects
  • Some observational data link low DHEA levels with depression
  • Small pilot studies suggested benefit

Evidence:

  • Small trials (n=20-50) showed some benefit
  • Larger trials failed to replicate findings
  • Not recommended as primary treatment for depression
  • May have role as adjunct in refractory depression (investigational)

Current Status:

  • Not FDA-approved for depression
  • Not recommended by psychiatric treatment guidelines
  • Standard antidepressants far more effective

12.8 DHEA for Bone Health

Rationale:

  • DHEA converts to estrogens and androgens, both support bone density
  • Observational studies link low DHEA with osteoporosis risk

RCT Evidence:

  • No consistent benefit on bone mineral density
  • No evidence for fracture prevention
  • Effects modest at best

Recommendation:

  • Not recommended for osteoporosis prevention or treatment
  • Standard therapies (bisphosphonates, denosumab, estrogen) far more effective

12.9 DHEA for Infertility/Ovarian Reserve

Off-Label Use:

  • Some fertility clinics use DHEA for diminished ovarian reserve
  • Dose: 25-75 mg daily for 2-4 months before IVF

Evidence:

  • Mostly observational studies and case series
  • Few small RCTs with conflicting results
  • Some studies suggest improved ovarian response in poor responders
  • No large, well-designed RCTs

Expert Opinion:

  • Controversial; not universally accepted
  • May benefit select patients (poor ovarian reserve)
  • Specialist supervision essential
  • Not FDA-approved for this indication

12.10 DHEA for Systemic Lupus Erythematosus (SLE)

Rationale:

  • Immunomodulatory effects of DHEA
  • Observational data linking low DHEA with disease activity

Clinical Trials:

  • Small trials showed some benefit on disease activity and fatigue
  • Larger trials had mixed results
  • Not recommended by rheumatology guidelines

Current Status:

  • Not FDA-approved for SLE
  • Not routinely used in clinical practice

12.11 DHEA for Athletic Performance

Claims:

  • Marketed to athletes for muscle building, strength, performance

Evidence:

  • No convincing evidence for performance enhancement
  • Minimal effects on muscle mass or strength in controlled trials
  • Banned by sports organizations despite lack of proven benefit

Recommendation:

  • Not recommended for athletes
  • Risk of doping violations
  • No evidence of efficacy

12.12 Summary of Clinical Evidence

Strong Evidence (Recommended):

  • Intravaginal DHEA for vulvovaginal atrophy (FDA-approved)

Moderate Evidence (Consider on individual basis):

  • Oral DHEA for women with adrenal insufficiency and symptoms

Weak or No Evidence (Not recommended):

  • DHEA in men with adrenal insufficiency (routine use)
  • Anti-aging/general wellness
  • Sexual dysfunction (except vulvovaginal atrophy)
  • Depression (primary treatment)
  • Bone health
  • Athletic performance
  • Cognitive function

Investigational (Insufficient evidence):

  • Diminished ovarian reserve/infertility
  • SLE
  • Depression (adjunctive treatment)

13. Comparison to Alternatives

13.1 DHEA vs. Testosterone for Androgens in Women

Key Comparisons:

The only evidence-based indication for testosterone therapy in women is treating hypoactive sexual desire disorder after menopause, while vaginal DHEA (prasterone) has been FDA-approved for treatment of moderate to severe dyspareunia.

Mechanism:

DHEA is a precursor hormone, while testosterone is a fully active end hormone. DHEA and androstenedione are main prohormones that are peripherally converted to the active androgens testosterone and dihydrotestosterone.

FDA Approval Status:

Effects on Hormone Levels:

A 2024 meta-analysis of 21 studies found that DHEA supplementation significantly increased estradiol (7.86 pg/mL) and testosterone levels (24.31 ng/dL) in postmenopausal women.

In women but not in men, DHEA increased testosterone and DHT to levels above gender-specific young adult ranges. The magnitude of testosterone increment was higher in females compared to men.

Clinical Differences:

FeatureDHEATestosterone
FDA approval (women)Vaginal onlyNone
MechanismProhormone (converts to T and E2)Active androgen
Estrogenic effectsYes (aromatization)Minimal
Androgenic effectsModerate (via conversion)High (direct)
Customizable dosingLimited (supplement variable quality)Yes (compounded)
CostLow ($6-11/month oral)Moderate-high (compounded)
MonitoringDHEA-S, testosterone, estradiolTestosterone
ReversibilityFully reversibleMostly reversible (voice changes may not be)

Advantages of DHEA:

  • Provides both androgens and estrogens (may benefit postmenopausal women)
  • Less potent androgenic effects (lower risk of virilization)
  • Lower cost
  • Available OTC (though quality variable)

Disadvantages of DHEA:

  • Variable inter-individual response
  • Quality concerns with OTC products
  • Less potent (may be inadequate for some)
  • Modest evidence for efficacy

Advantages of Testosterone:

  • More potent androgen (effective for sexual dysfunction)
  • Pharmaceutical-grade compounded products available
  • More predictable dose-response

Disadvantages of Testosterone:

  • Not FDA-approved for women
  • Higher risk of virilization
  • More expensive
  • Requires compounding pharmacy

When to Choose DHEA:

  • Adrenal insufficiency in women (androgen deficiency)
  • Postmenopausal women desiring both androgen and estrogen effects
  • Patients preferring "natural" prohormone approach
  • Cost-conscious patients

When to Choose Testosterone:

  • Severe hypoactive sexual desire disorder (off-label)
  • Inadequate response to DHEA
  • Desire for more potent androgen effects
  • Willingness to pay for compounded product

13.2 Intravaginal DHEA vs. Vaginal Estrogen

For Vulvovaginal Atrophy:

FeatureIntravaginal DHEA (Intrarosa)Vaginal Estrogen
FDA approvalYes (dyspareunia)Yes (vulvovaginal atrophy)
MechanismConverts to E2 and T locallyDirect estrogenic effect
Systemic absorptionMinimalMinimal
EfficacyComparable to vaginal estrogenWell-established
CostHigh ($300-500/month)Moderate ($30-100/month)
Generic availableNoYes (estradiol cream)
Androgenic effectsYes (local testosterone)No
FormulationsInsert onlyCream, tablet, ring

Clinical Equivalence:

  • Both effective for dyspareunia and vaginal dryness
  • Both have minimal systemic absorption
  • Both improve vaginal maturation index

Advantages of Intravaginal DHEA:

  • May be preferred by women who want to avoid estrogen
  • Provides local androgens in addition to estrogens
  • Minimal systemic estrogen exposure

Disadvantages of Intravaginal DHEA:

  • Much more expensive
  • No generic available
  • Limited formulation options

Advantages of Vaginal Estrogen:

  • Lower cost
  • Generic available (estradiol cream)
  • Multiple formulations (cream, tablet, ring)
  • Longer track record

Disadvantages of Vaginal Estrogen:

  • Some women prefer to avoid estrogen (even local)
  • No androgenic effects

Clinical Decision-Making:

  • First-line: Vaginal estrogen (lower cost, established efficacy)
  • Consider Intravaginal DHEA if:
    • Patient prefers non-estrogen option
    • Inadequate response to vaginal estrogen
    • Desire for androgenic effects
    • Insurance coverage favorable

Women using vaginal DHEA should not have blood hormone levels checked, as serum concentration is minimally affected.

13.3 DHEA vs. Combined Estrogen-Androgen Therapy

For Postmenopausal Women:

DHEA:

  • Single agent providing both E2 and T via peripheral conversion
  • Variable individual conversion rates
  • Lower cost

Combined E+T:

  • Separate estrogen and testosterone administration
  • Customizable doses of each
  • More predictable hormone levels
  • Higher cost

Clinical Context:

  • Most postmenopausal HRT: Estrogen ± progestogen (no androgen)
  • Adding androgens (DHEA or testosterone): Controversial, not standard
  • Evidence for combined E+T therapy limited

13.4 DHEA vs. Standard HRT in Adrenal Insufficiency

For Women with Primary Adrenal Insufficiency:

Standard Replacement:

  • Hydrocortisone (glucocorticoid)
  • Fludrocortisone (mineralocorticoid)
  • DHEA (optional adrenal androgen replacement)

Decision to Add DHEA:

Indications for DHEA:

  • Persistent symptoms despite adequate gluco/mineralocorticoid replacement
  • Low DHEA-S levels
  • Symptoms of androgen deficiency (low libido, fatigue, mood)
  • Patient preference for trial

Not routinely recommended:

  • Many women with adrenal insufficiency do well without DHEA
  • Modest evidence for benefit
  • Individual trial warranted if symptomatic

13.5 DHEA vs. Other "Anti-Aging" Supplements

Common "Anti-Aging" Supplements:

  • Growth hormone (GH)
  • Melatonin
  • Coenzyme Q10
  • Resveratrol
  • NAD+ precursors

DHEA Comparison:

Relative to GH:

  • DHEA less potent, safer
  • GH more expensive, requires injection, more side effects
  • Neither recommended for anti-aging

Relative to Other Supplements:

  • DHEA has hormonal effects (others don't)
  • DHEA has more potential for adverse effects
  • DHEA has slightly more evidence (though still limited)

Recommendation:

  • None of these supplements proven for anti-aging
  • DHEA has more risks than most supplements due to hormonal effects
  • Not recommended for healthy aging

13.6 Decision-Making Algorithm

For Women with Adrenal Insufficiency:

  1. Ensure adequate gluco/mineralocorticoid replacement first
  2. Assess for DHEA deficiency:
    • DHEA-S level low?
    • Symptoms of androgen deficiency?
  3. Consider 3-6 month trial of DHEA 25-50 mg
  4. Reassess response:
    • Clear benefit? Continue
    • No benefit? Discontinue
    • Intolerable side effects? Discontinue

For Vulvovaginal Atrophy:

  1. First-line: Vaginal estrogen (lower cost)
  2. If inadequate or patient prefers non-estrogen: Intravaginal DHEA

For Other Indications:

  • Generally not recommended
  • Limited evidence
  • Risks may outweigh benefits

14. Storage and Handling

14.1 Storage Temperature and Conditions

Oral DHEA Supplements:

DHEA supplements (in tablet form) should be stored at 68°F to 77°F (20°C to 25°C) in tightly sealed, light-resistant containers with child-resistant closures.

Storage Recommendations:

  • Temperature: Room temperature (68-77°F / 20-25°C)
  • Humidity: Store in dry place; avoid bathrooms
  • Light: Protect from direct sunlight (amber bottles provide protection)
  • Container: Keep in original container with desiccant packet
  • Child safety: Use child-resistant closures

Intravaginal DHEA (Intrarosa):

  • Follow product labeling for specific storage requirements
  • Generally room temperature
  • Protect from moisture and heat
  • Keep in original packaging until use

14.2 Shelf Life and Expiration

Shelf Life:

The shelf life for DHEA is typically three years from the manufacture date.

Expiration Dating:

Factors Affecting Stability:

  • Heat: Accelerates degradation
  • Moisture: Can degrade tablets
  • Light: May affect potency
  • Time: Gradual loss of potency even under ideal conditions

14.3 Signs of Degradation

Visual Inspection:

Before each use, inspect tablets:

  • Color: Should be uniform (white to off-white typical)
  • Discoloration: Yellowing or darkening suggests degradation
  • Texture: Crumbling, sticking together indicates moisture damage
  • Odor: Strong or unusual odor may indicate degradation

When to Discard:

  • Visual changes (color, texture)
  • Past expiration date
  • Stored improperly (extreme heat, moisture)
  • Suspicious odor

14.4 Handling Precautions

For Patients:

General Handling:

  • Wash hands before handling tablets
  • Take only the number of tablets needed
  • Do not return tablets to bottle after handling
  • Keep desiccant packet in bottle (absorbs moisture)

Child Safety:

  • Keep out of reach of children
  • Hormonal effects potentially harmful if ingested by children
  • Use child-resistant containers

Disposal:

Proper Disposal Methods:

  • Do NOT flush down toilet (environmental contamination)
  • Do NOT throw directly in trash

Recommended Disposal:

  1. Drug Take-Back Programs:

    • DEA National Prescription Drug Take-Back Day
    • Local pharmacy take-back programs
    • Household hazardous waste facilities

  2. Household Disposal (if take-back unavailable):

    • Remove from original container
    • Mix with undesirable substance (coffee grounds, cat litter)
    • Place in sealed bag or container
    • Dispose in household trash
    • Scratch out personal information on label before discarding bottle

14.5 Travel Considerations

Domestic Travel:

  • Carry in original container
  • Bring sufficient supply for trip duration plus extra
  • Keep in carry-on luggage (temperature-controlled)
  • If OTC supplement: No prescription needed
  • If vaginal DHEA (Intrarosa): Bring prescription

International Travel:

  • DHEA regulations vary by country
  • Research destination country laws
  • Carry prescription or doctor's letter (even for OTC in US)
  • Some countries may not allow import
  • Declare at customs if required

Temperature Considerations:

  • Avoid leaving in hot car
  • Use insulated bag if traveling to hot climates
  • Room temperature generally acceptable for short trips

14.6 Product Quality and Selection

Third-Party Testing:

For OTC DHEA supplements, look for:

  • USP (United States Pharmacopeia) verification
  • NSF International certification
  • ConsumerLab testing

Reputable Brands:

  • Established supplement companies
  • Brands with independent testing
  • GMP (Good Manufacturing Practices) certified facilities

Avoid:

  • Suspiciously cheap products
  • Unknown brands
  • Products with proprietary blends (unclear DHEA content)
  • International sources of uncertain quality

14.7 Pharmaceutical-Grade vs. Supplement-Grade

Supplement-Grade (OTC):

  • Variable quality
  • Not FDA-regulated for quality
  • Actual content may differ from label
  • Less expensive

Pharmaceutical-Grade (Compounded):

  • Higher quality standards
  • Compounding pharmacy regulated by state boards
  • More consistent potency
  • Requires prescription
  • More expensive

Intrarosa (FDA-Approved):

  • Highest quality standards
  • FDA-approved manufacturing
  • Consistent quality and potency
  • Most expensive

Proper storage in a dark, dry place helps preserve quality, though HRT medications, including DHEA, can degrade over time, especially when exposed to heat, moisture, or light.

15. Goal Archetype Integration

15.1 Primary Goal Alignment

GoalRelevanceRole of DHEA
Fat LossLowMinimal direct effect; inconsistent data on body composition. May support metabolism indirectly through hormone optimization
Muscle BuildingLowLimited evidence for lean mass gains; not recommended as ergogenic aid. Modest conversion to testosterone insufficient for significant anabolic effect
LongevityModerateAge-related decline correlates with aging biomarkers; observational data links higher DHEA-S with longevity, but causal relationship unproven
Healing/RecoveryLowNo direct tissue repair evidence; indirect support through hormone balance
Cognitive OptimizationLow-ModerateNeurosteroid effects (GABA-A, NMDA, sigma-1 receptor modulation); clinical trials show no consistent cognitive benefit
Hormone OptimizationHighPrimary role as hormone precursor; restores androgen/estrogen levels in deficiency states
Sexual WellnessModerateFDA-approved for vulvovaginal atrophy (Intrarosa); mixed evidence for libido improvement
Adrenal SupportHighDirect replacement of adrenal androgen in insufficiency states; addresses zona reticularis output
Anti-AgingLow (No Evidence)Widely marketed but no evidence supports reversal of aging; age-related decline may be physiological adaptation
Mood/Well-BeingModerateSmall improvements in depression scores in adrenal insufficiency; neurosteroid effects on mood regulation

15.2 When DHEA Makes Sense

Primary Indications:

  • Women with primary adrenal insufficiency and symptoms of androgen deficiency (fatigue, low libido, decreased well-being) despite adequate glucocorticoid/mineralocorticoid replacement
  • Postmenopausal women with vulvovaginal atrophy/dyspareunia (Intrarosa - FDA-approved)
  • Women with secondary adrenal insufficiency with documented low DHEA-S and persistent symptoms

Secondary Considerations:

  • Postmenopausal women seeking both androgen and estrogen effects from a single agent
  • Women with documented low DHEA-S for age and symptoms consistent with androgen deficiency
  • Fertility patients with diminished ovarian reserve (specialist supervision, investigational)

Best Responder Profile:

  • Female sex (women benefit more than men from DHEA replacement)
  • Documented low DHEA-S levels
  • Symptomatic (fatigue, low libido, mood changes)
  • Adrenal insufficiency (primary or secondary)
  • Age 40+ with age-related DHEA decline

15.3 When to Choose Something Else

ScenarioBetter AlternativeRationale
Male hypogonadismTestosterone, Enclomiphene, HCGMen produce testosterone primarily from testes; DHEA adds minimal androgen contribution
Female sexual dysfunction (severe)Compounded testosteroneMore potent, predictable androgen effect for hypoactive sexual desire disorder
OsteoporosisBisphosphonates, Denosumab, EstrogenNo evidence DHEA prevents fractures; standard therapies proven effective
DepressionSSRIs, SNRIs, standard antidepressantsDHEA not recommended as primary treatment; evidence weak
Athletic performanceNone (training focus)DHEA banned by WADA; no evidence of performance benefit
Anti-agingLifestyle optimization (exercise, diet, sleep)No evidence DHEA extends lifespan or reverses aging
Men with adrenal insufficiencyAdequate gluco/mineralocorticoid replacementDHEA rarely beneficial in men; testicular T production dominates
Cognitive declineEvidence-based cognitive interventionsNo evidence DHEA improves cognition
Primary cortisol deficiencyHydrocortisoneDHEA does not replace cortisol; different pathways

16. Age-Stratified Dosing

16.1 Age-Related DHEA Decline: The Clinical Context

DHEA and DHEA-S follow a characteristic age trajectory that informs dosing decisions:

Peak and Decline Pattern:

  • Birth: High fetal zone production, then rapid decline in first year
  • Ages 6-8 (Adrenarche): Production begins increasing
  • Ages 20-30 (Peak): Maximum DHEA-S levels reached
    • Men: Peak median ~286 mcg/dL at age 20-24
    • Women: Peak median ~250 mcg/dL at age 17-24
  • After age 30: Decline of 2-3% per year
  • Ages 70-80: Levels fall to 10-20% of peak values
    • Men: Median ~90 mcg/dL by age 75+
    • Women: Median ~50-70 mcg/dL by age 75+

Clinical Significance: The age-related decline has led some to propose "DHEA replacement" for healthy aging. However, evidence does not support routine supplementation in healthy elderly without documented deficiency states.

16.2 Age-Stratified Dosing Guidelines

Age BracketStarting DoseTarget DHEA-S RangeAdjustment NotesClinical Rationale
20-35Generally not indicatedN/AOnly if documented deficiency (e.g., adrenal insufficiency)DHEA naturally at peak; supplementation rarely needed
35-5025 mg daily200-350 mcg/dL (women)May increase to 50 mg if no response after 8-12 weeksBeginning of natural decline; replacement if symptomatic with low levels
50-6525 mg daily150-300 mcg/dL (women)Standard replacement dose; titrate by symptoms and labsMore significant decline; replacement more commonly considered
65+10-25 mg daily100-200 mcg/dL (women)Start low, titrate slowly; increased sensitivity to hormonal effectsElderly may have enhanced sensitivity; start conservatively

16.3 Sex-Specific Considerations

Males

Dosing:

  • Standard dose (if indicated): 25 mg daily
  • Typical range: 25-50 mg daily (rarely needed)
  • Maximum: 50 mg daily

Key Considerations:

  • DHEA replacement NOT routinely recommended in men
  • Testes produce substantial testosterone (>90% of total androgens)
  • DHEA contributes minimally to total androgen pool in men
  • Clinical trials consistently show no benefit in men with adrenal insufficiency alone
  • Consider only if: Combined adrenal insufficiency AND hypogonadism, or documented low DHEA-S with persistent symptoms despite other therapies

Monitoring in Men:

  • PSA annually (prostate cancer screening)
  • Total and free testosterone
  • Signs of androgenic excess
  • Prostate symptoms (BPH)

Females

Dosing:

  • Starting dose: 25 mg daily
  • Standard replacement: 25-50 mg daily
  • Target: Mid to high-normal DHEA-S range for young adult women

Key Considerations:

  • Women benefit more from DHEA replacement than men
  • DHEA is the primary androgen precursor in women (adrenal source)
  • Ovarian contribution to androgens declines after menopause
  • Clinical trials show modest improvements in quality of life, mood in women with adrenal insufficiency

Menstrual Cycle Considerations:

  • No specific cycle-based dosing adjustments required
  • DHEA-S levels remain relatively stable throughout cycle
  • Monitor for menstrual irregularities as potential side effect

Pregnancy and Fertility:

  • CONTRAINDICATED in pregnancy (risk of fetal virilization)
  • Women of reproductive age must use effective contraception
  • Discontinue immediately if pregnancy suspected
  • For fertility (diminished ovarian reserve): Specialist supervision required; doses 25-75 mg daily used off-label

Menopause-Specific:

  • Postmenopausal women may benefit from both androgenic and estrogenic effects
  • Intravaginal DHEA (Intrarosa 6.5 mg) FDA-approved for dyspareunia
  • Systemic DHEA: 25-50 mg daily if symptoms of androgen deficiency

16.4 DHEA-S Reference Ranges by Age and Sex

Women - Age-Specific Reference Ranges (mcg/dL):

AgeLow NormalHigh NormalOptimal Target (Wellness)
18-19145395275-395
20-2965380275-380
30-3945270200-270
40-4932240150-240
50-5926200100-200
60-691313080-130
70+179050-90

Men - Age-Specific Reference Ranges (mcg/dL):

AgeLow NormalHigh NormalOptimal Target (Wellness)
18-29110510350-500
30-39110370280-370
40-4945345200-345
50-5925240150-240
60+20204100-180

Note: Optimal targets for "wellness" perspectives suggest mid-upper range of young adult levels, but evidence does not support aggressive replacement in healthy individuals.

17. Drug Interactions - Comprehensive

17.1 Interactions with TRT (Testosterone Replacement Therapy)

AspectInteraction DetailsManagement
MechanismAdditive androgen effect; DHEA converts to testosteroneMonitor combined testosterone levels
SeverityModerateCaution required
Effect on T LevelsDHEA increases testosterone 15-30 ng/dL on average in women; smaller effect in menMay need to reduce TRT dose
Side Effect RiskIncreased androgenic side effects (acne, hair loss, hirsutism)Monitor for virilization
When CombinedTypically in women with adrenal insufficiency already on TRTRarely needed; assess necessity
Dosing AdjustmentIf using both, start DHEA at 25 mg; recheck testosterone at 4-6 weeksAdjust TRT dose based on total androgen levels

Clinical Note: Combining DHEA with TRT is uncommon. In most cases, choose one or the other based on clinical indication.

17.2 Interactions with Aromatase Inhibitors

AspectInteraction DetailsManagement
MechanismAromatase inhibitors (AIs) block conversion of DHEA to estrogensShifts DHEA metabolism toward androgens
EffectReduced estrogenic benefits; increased androgenic effectsMay worsen androgenic side effects
Clinical ContextBreast cancer patients on AIs (anastrozole, letrozole, exemestane)Generally AVOID DHEA with AIs
Rationale for AvoidanceDHEA may partially counteract AI efficacy; theoretical cancer riskUse alternative therapies
ExceptionIntravaginal DHEA (minimal systemic absorption) may be consideredOncologist consultation required

17.3 Interactions with Estrogen Therapy

AspectInteraction DetailsManagement
MechanismDHEA converts to estradiol; additive estrogenic effectMonitor estradiol levels
SeverityModerateCaution required
Symptoms of ExcessBreast tenderness, bloating, nausea, headacheReduce estrogen or DHEA dose
Cancer Risk ConsiderationCombined estrogen load may increase hormone-sensitive cancer riskMonitor closely
Postmenopausal WomenDHEA + estrogen rarely necessary; DHEA alone provides bothConsider DHEA alone vs. estrogen alone
Lab MonitoringCheck estradiol at baseline and 8-12 weeksTarget appropriate range for age

17.4 Interactions with Other Hormone Compounds

CompoundInteractionEffectRecommendation
PregnenoloneBoth are steroid precursors; additive hormone effectsMay increase multiple downstream hormonesUse one or the other unless specialist-guided
HCGHCG stimulates gonadal hormone production; DHEA adds adrenal contributionPossible testosterone excessMonitor testosterone; typically not combined
ProgesteroneMinimal direct interaction; both support hormone balanceGenerally safe to combineNo specific adjustment needed
Thyroid HormonesUnclear interaction; may affect metabolismVariableMonitor thyroid function periodically
Growth Hormone / IGF-1No direct pharmacokinetic interactionAdditive anti-aging claims (both unproven)No specific interaction management
Clomiphene/EnclomipheneBoth increase testosterone; different mechanismsAdditive androgenic effectTypically not combined

17.5 Common Prescription Drug Interactions

Drug ClassExamplesInteractionSeverityManagement
AnticoagulantsWarfarin, aspirinMay affect platelet functionModerateMonitor INR; watch for bleeding
AntidepressantsSSRIs, SNRIs, TCAsIncreased mood instability risk; mania riskModerateClose psychiatric monitoring
AntipsychoticsPimozideCYP3A4 inhibition; QT prolongationMajor (Contraindicated with pimozide)Avoid pimozide
Insulin/Diabetes MedsMetformin, sulfonylureas, insulinVariable glucose effectsModerateMonitor blood glucose closely
ImmunosuppressantsTacrolimus, cyclosporine, everolimusCYP3A4 interaction; increased drug levelsModerateMonitor drug levels
CorticosteroidsPrednisone, hydrocortisoneComplex hormonal interplayMinor-ModerateCommon in adrenal insufficiency; standard monitoring
AntihypertensivesVariousDHEA may affect blood pressureMinorMonitor blood pressure

17.6 Supplement Interactions

SupplementInteractionNotes
Other androgen precursors (Androstenedione, 7-Keto DHEA)Additive androgenic effectsAvoid combining
Phytoestrogens (Soy isoflavones, Red clover)Additive estrogenic effectsUse caution
St. John's WortCYP3A4 induction; may reduce DHEA levelsMonitor for reduced efficacy
Licorice rootMineralocorticoid effects; electrolyte/BP effectsUse caution; monitor potassium, BP
Saw PalmettoBoth affect androgen pathwaysMay have additive effects on prostate
MacaBoth claimed for hormonal supportNo known adverse interaction
AshwagandhaBoth may affect hormonesLimited interaction data

17.7 Food and Timing Interactions

FactorInteractionRecommendation
FoodMinimal effect on absorptionCan take with or without food
Grapefruit juiceCYP3A4 inhibition; may increase DHEA metabolite levelsAvoid large quantities
AlcoholAcute: CNS effects; Chronic: affects liver metabolismModerate intake generally acceptable
Time of dayPhysiological DHEA secretion peaks in morningTake in morning to mimic natural rhythm
Other hormone timingIf on hydrocortisone, take DHEA separatelySpace from other hormone doses

18. Bloodwork Impact & Monitoring

18.1 Expected Marker Changes

MarkerExpected ChangeDirectionTimelineClinical Notes
DHEA-SPrimary target; dose-dependent increase↑2-4 weeks to steady stateMain monitoring marker
Testosterone (Total)Moderate increase (women); minimal (men)↑4-8 weeksWomen: 15-30 ng/dL increase typical
Free TestosteroneParallels total T↑4-8 weeksMay increase more proportionally
Estradiol (E2)Modest increase via aromatization↑4-8 weeksWomen: 5-10 pg/mL increase typical
AndrostenedioneIncreases (DHEA metabolite)↑2-4 weeksNot routinely monitored
DHTMay increase (via 5α-reductase)↑4-8 weeksRelevant for androgenic side effects
HDL CholesterolMay decrease↓8-12 weeksUnfavorable; monitor lipid panel
LDL CholesterolVariable↔8-12 weeksLess consistent effect
TriglyceridesVariable↔8-12 weeksMonitor in lipid panel
Liver Enzymes (ALT, AST)Usually stable↔OngoingRare elevations; monitor if risk factors
PSA (Men)May increase↑VariableMonitor annually; androgenic effect on prostate
Fasting Glucose/HbA1cVariable↔8-12 weeksInconsistent effects; monitor in diabetics

18.2 DHEA-S Target Levels by Age

Goal: Restore to mid-upper range of young adult levels (for indicated patients)

AgeTarget DHEA-S (Women, mcg/dL)Target DHEA-S (Men, mcg/dL)
35-50200-300250-350
50-65150-250180-280
65+100-180120-200

Note: These are general targets. Individual titration based on symptoms and side effects is essential.

18.3 Monitoring Schedule

TimepointRequired TestsOptional TestsClinical Assessment
BaselineDHEA-S, Testosterone (total/free), Estradiol, Lipid panel, LFTs, Fasting glucose, PSA (men)FSH/LH, Prolactin, CBCFull history, physical, symptom baseline
4-6 weeksNone routinelyDHEA-S if concern about absorptionClinical response, side effects
8-12 weeksDHEA-S, Testosterone, EstradiolFull lipid panel if baseline abnormalEfficacy assessment, side effect review
6 monthsDHEA-S, Testosterone, Lipid panelEstradiol, LFTsComprehensive review; continue/adjust/discontinue
12 monthsDHEA-S, Testosterone, Estradiol, Lipid panel, LFTs, PSA (men)HbA1c if diabeticAnnual comprehensive assessment
Ongoing (yearly)DHEA-S, Testosterone, Lipid panel, LFTs, PSA (men)Per clinical indicationAnnual review; reassess need for continuation

18.4 Red Flags in Labs

FindingThresholdAction
DHEA-S extremely high>600 mcg/dL (women), >700 mcg/dL (men)Rule out adrenal tumor; reduce dose; specialist referral
Testosterone supraphysiologic>70 ng/dL (women), >1000 ng/dL (men)Reduce DHEA dose; assess for excess
Estradiol elevated>400 pg/mL (either sex)Reduce DHEA dose; evaluate for other sources
HDL significant drop>25% decline from baseline or <40 mg/dLConsider dose reduction; cardiovascular risk assessment
Liver enzymes elevated>3x upper limit of normalDiscontinue DHEA; hepatology evaluation
PSA increase (men)>4.0 ng/mL or >0.75 ng/mL/year riseUrology referral; consider discontinuing
Hematocrit elevated (men)>54%Usually not DHEA-related; evaluate if on TRT concurrently

18.5 Labs + Symptoms Integration

Lab FindingSymptomInterpretationAction
Low DHEA-S + Fatigue, low libidoClassic DHEA deficiencyConsider DHEA trialStart 25 mg daily
Normal DHEA-S + Fatigue, low libidoDHEA not the issueEvaluate other causesDo not start DHEA
Elevated T + Acne, hirsutismAndrogenic excessOver-replacementReduce DHEA dose
Elevated E2 + Breast tendernessEstrogenic excessOver-conversion to estrogenReduce DHEA dose
Improved DHEA-S + No symptom improvementNon-responderDHEA may not be beneficial for this patientConsider discontinuation after 3-6 months
Improved DHEA-S + Symptom improvementGood responseContinue therapyMaintain current dose
Low HDL + No symptomsMetabolic side effectCardiovascular riskRisk-benefit discussion; consider alternatives

18.6 Marker-Based Dose Adjustment

Adjustment by Baseline Markers

Baseline MarkerIf HighIf LowIf Normal
DHEA-SGenerally do not supplementPrimary indication for supplementationConsider only if symptomatic
Testosterone (women)Avoid DHEA (risk of excess)DHEA may help; start 25 mgStandard starting dose if indicated
Estradiol (women)Caution; DHEA adds moreDHEA provides estrogen via conversionStandard approach
HDL CholesterolCaution; DHEA may lower furtherMore flexibilityMonitor closely

Adjustment by Response Markers

On-Treatment FindingAdjustment
Good symptom response + DHEA-S in target range + No side effectsMaintain current dose
Poor symptom response + DHEA-S in target range + No side effectsConsider increasing dose (max 50 mg women) or discontinue if no response after 3-6 months
Good symptom response + DHEA-S above targetReduce dose; may tolerate lower dose
Any response + Side effects (androgenic)Reduce dose
Any response + HDL significant declineRisk-benefit discussion; may need to reduce or discontinue
No response after 3-6 monthsDiscontinue; DHEA not appropriate for this patient

19. Protocol Integration

19.1 Standalone DHEA vs. Combined Protocols

Standalone DHEA Protocol

When Appropriate:

  • Women with adrenal insufficiency as sole androgen deficiency
  • Postmenopausal women desiring mild androgen/estrogen support without prescription HRT
  • Vulvovaginal atrophy (intravaginal formulation)
  • Trial for non-specific symptoms in women with documented low DHEA-S

Protocol:

  1. Baseline labs: DHEA-S, testosterone, estradiol, lipid panel, LFTs
  2. Start DHEA 25 mg orally each morning
  3. Recheck labs at 8-12 weeks
  4. Adjust dose based on response and labs (max 50 mg daily)
  5. Reassess at 3-6 months; discontinue if no benefit

DHEA with TRT Protocol (Rare, Specialized)

When Considered:

  • Women with combined adrenal insufficiency AND inadequate TRT response
  • Typically NOT recommended; assess if TRT dose adjustment or alternative approach preferable

Protocol:

  1. Optimize TRT first; confirm indication for adding DHEA
  2. If adding DHEA, start at 15-25 mg daily
  3. Monitor total testosterone, free testosterone, DHEA-S at 4-6 weeks
  4. Watch closely for androgenic side effects
  5. Typically discontinue DHEA if no clear additive benefit

19.2 DHEA vs. Pregnenolone: Clinical Decision Guide

FactorChoose DHEAChoose Pregnenolone
Primary GoalAndrogen/estrogen supportNeurosteroid/cortisol pathway support
Target PathwaySex hormone synthesis (T, E2)Cortisol, progesterone, neurosteroids
Key SymptomsLow libido, fatigue, mood (androgen-related)Cognitive fog, stress intolerance, memory
Lab FindingLow DHEA-SLow 17-OH progesterone + low cortisol
Adrenal InsufficiencyFirst choice for androgen replacementConsider if cortisol pathway support needed
Cognitive FocusSecondary optionPrimary option (neurosteroid effects)
Sex DifferenceMore evidence in womenSimilar for both sexes
Age-Related DeclineMore pronounced declineMore gradual decline

Can They Be Combined?

  • Generally, use one or the other
  • If combining: Start one at a time to assess individual response
  • Typical combined protocol: Pregnenolone 25 mg AM + DHEA 25 mg AM
  • Monitor multiple hormone levels if combining

19.3 Timing Considerations with Other Compounds

If Also TakingTiming with DHEARationale
HydrocortisoneSeparate by 2-4 hoursAvoid confusion of effects; different pathways
FludrocortisoneAny timeNo interaction
Thyroid hormoneSpace 4 hours from T4General supplement spacing
Testosterone (topical)DHEA AM, T per usual scheduleNo specific timing requirement
Estrogen (oral)Both AM usuallyNo specific timing requirement
ProgesteroneProgesterone typically PM; DHEA AMFollow usual progesterone timing
GH/PeptidesGH typically PM; DHEA AMNo interaction; different mechanisms
MelatoninMelatonin PM; DHEA AMOpposite circadian timing

19.4 Integration with Lifestyle Pillars

PillarIntegration Point
NutritionNo specific dietary requirements; adequate cholesterol intake supports hormone synthesis; avoid excessive alcohol (liver metabolism); maintain healthy weight (adipose tissue affects hormone conversion)
ActivityRegular exercise supports hormone optimization; resistance training may enhance DHEA's modest effects on body composition; avoid overtraining (adrenal stress)
SleepDHEA naturally follows circadian rhythm (peak AM); take DHEA in morning; adequate sleep supports overall hormonal health
Stress ManagementChronic stress depletes adrenal reserve; stress management complements DHEA's adrenal support role; cortisol and DHEA have interrelated patterns
MindsetMood benefits modest; DHEA not a replacement for mental health treatment; set realistic expectations for supplement-level interventions

19.5 Protocol Templates

Template 1: DHEA for Adrenal Insufficiency (Women)

Indication: Primary or secondary adrenal insufficiency with symptoms of androgen deficiency

Prerequisites:

  • Stable glucocorticoid and mineralocorticoid replacement
  • Documented low DHEA-S
  • Symptoms: fatigue, low libido, decreased well-being

Protocol:

  • Week 1-12: DHEA 25 mg orally each morning
  • Week 8-12: Recheck DHEA-S, testosterone, estradiol, lipid panel
  • Week 12: Assess response
    • If improved: Continue, consider dose adjustment
    • If no improvement: Consider increasing to 50 mg daily
  • Month 6: Comprehensive reassessment
  • Ongoing: Monitor every 6-12 months

Template 2: Intravaginal DHEA for Vulvovaginal Atrophy

Indication: Moderate to severe dyspareunia due to vulvovaginal atrophy (postmenopausal)

Prerequisites:

  • Postmenopausal status confirmed
  • Symptoms of vulvovaginal atrophy

Protocol:

  • Intrarosa 6.5 mg insert intravaginally at bedtime daily
  • Week 4-6: Assess response
  • Week 12: Maximum benefit typically achieved
  • Ongoing: Continue as needed; symptoms recur with discontinuation
  • Note: Do NOT check serum hormone levels (minimal systemic absorption)

Template 3: DHEA for Age-Related Decline (If Elected)

Indication: Documented low DHEA-S with symptoms, after ruling out other causes

Prerequisites:

  • DHEA-S below age-specific reference range
  • Symptoms consistent with hormone deficiency
  • Other causes excluded
  • Patient understands limited evidence for this indication

Protocol:

  • Start: DHEA 10-25 mg orally each morning
  • Week 8-12: Recheck DHEA-S, basic labs
  • Month 3: Assess symptom response
    • Clear improvement: Continue
    • No improvement: Discontinue (DHEA unlikely to help)
  • If continuing: Annual reassessment of need
  • Goal: Symptom improvement, not arbitrary lab targets

References

  1. Pharmaceutical Approval Update - PMC

  2. Prescribing of FDA-approved and compounded hormone therapy differs by specialty - PMC

  3. DHEA - Mayo Clinic

  4. DHEA: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews - WebMD

  5. DHEA Dosage Guide - GoodRx

  6. Prasterone - Wikipedia

  7. Dehydroepiandrosterone - Wikipedia

  8. Dehydroepiandrosterone and Its Metabolite 5-Androstenediol: New Therapeutic Targets and Possibilities for Clinical Application - PMC

  9. Ample Evidence: Dehydroepiandrosterone (DHEA) Conversion into Activated Steroid Hormones Occurs in Adrenal and Ovary in Female Rat - PMC

  10. Novel mechanisms for DHEA action - Journal of Molecular Endocrinology

  11. Should Dehydroepiandrosterone Be Administered to Women? - PMC

  12. DHEA: why, when, and how much--DHEA replacement in adrenal insufficiency - PubMed

  13. Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency - New England Journal of Medicine

  14. Long-Term DHEA Replacement in Primary Adrenal Insufficiency: A Randomized, Controlled Trial - PMC

  15. DHEA replacement in women with adrenal insufficiency--pharmacokinetics, bioconversion and clinical effects - PubMed

  16. Treatment and Follow-up of Non-stress Adrenal Insufficiency - Journal of Clinical Research in Pediatric Endocrinology

  17. DHEA Supplements: Health Benefits, Uses, and Side Effects - WebMD

  18. What Are The Side Effects of DHEA? - Center for Human Reproduction

  19. Dehydroepiandrosterone Uses, Benefits & Dosage - Drugs.com

  20. DHEA Interactions Checker - Drugs.com

  21. DHEA herbal dosing, indications, interactions, adverse effects - Medscape

  22. DHEA supplements: Are they safe? Or effective? - Harvard Health

  23. DEHYDROEPIANDROSTERONE - Drugs in Pregnancy and Lactation

  24. Is DHEA Unsafe During Pregnancy? - Ovaterra

  25. Effects of dehydroepiandrosterone-sulphate (DHEA-S) administration on puerperal lactation - PubMed

  26. Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey - PubMed

  27. Dehydroepiandrosterone Replacement Administration: Pharmacokinetic and Pharmacodynamic Studies - Journal of Clinical Endocrinology & Metabolism

  28. Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone - PubMed

  29. DHEA Coupons & Cost Info for 2025 - SingleCare

  30. Dhea 2025 Prices, Coupons & Savings Tips - GoodRx

  31. Intrarosa 2025 Prices, Coupons & Savings Tips - GoodRx

  32. Dhea Coupons - WellRx

  33. DHEA Sulfate Test - MedlinePlus

  34. DHEAS Test - Cleveland Clinic

  35. Hormone Replacement Monitoring with Lab Tests - Walk-In Lab

  36. Lack of evidence supporting DHEA for improved overall health for women - Healio

  37. Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials of DHEA Treatment Effects on Quality of Life - Oxford Academic

  38. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects - PubMed

  39. Prescribing testosterone and DHEA: The role of androgens in women - Cleveland Clinic Journal of Medicine

  40. DHEA in Elderly Women and DHEA or Testosterone in Elderly Men - New England Journal of Medicine

  41. DHEA vs Testosterone: Natural vs Synthetic Hormonal Support - Swolverine

  42. Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women - Springer

  43. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) - PubMed

  44. How Long Does HRT Last? Expiration and Storage - Winona

  45. DHEA Expiration, Shelf Life - Just Answer

Document Information:

  • Document Title: Dehydroepiandrosterone (DHEA): Comprehensive Research Paper on Hormone Replacement Therapy
  • Date Created: December 2024
  • Purpose: Educational resource for healthcare professionals and patients
  • Scope: Complete review of DHEA including mechanism, clinical use, monitoring, safety, and evidence base
  • Intended Audience: Physicians, pharmacists, nurse practitioners, physician assistants, and informed patients

Disclaimer:

This document is for informational and educational purposes only. It does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Treatment decisions should be individualized based on patient-specific factors, current clinical guidelines, and professional medical judgment. DHEA use should be supervised by a healthcare provider, particularly given quality variability in over-the-counter supplements and limited evidence for many claimed benefits. Always consult with an endocrinologist or other qualified healthcare provider regarding diagnosis and treatment of adrenal insufficiency or other endocrine disorders.

Educational Information Only: DosingIQ provides educational information only. This is not medical advice. Consult a licensed healthcare provider before starting any supplement, peptide, or hormone protocol. Individual results may vary.